Oligosaccharide-containing composition
A novel oligosaccharide composition, including fucosylated and sialylated oligosaccharides with fructooligosaccharides, effectively promotes butyrate production in gut bacteria, addressing health issues related to inflammatory bowel disease and colorectal cancer.
Patent Information
- Application Number
- PCT/JP2026/017473
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing compositions do not effectively promote butyrate production by butyrate-producing bacteria to alleviate inflammatory bowel disease and colorectal cancer symptoms or maintain intestinal health.
A composition comprising fucosylated and sialylated oligosaccharides, such as 2'-fucosyllactose, 3'-sialyllactose, and 6'-sialyllactose, in combination with fructooligosaccharides, promotes butyrate production by co-culturing with bacteria like Faecalibacterium and Bifidobacterium bifidum.
Enhances butyrate production, supporting intestinal health and potentially treating related diseases by utilizing specific oligosaccharides and fructooligosaccharides to stimulate butyrate-producing bacteria.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure JPOXMLDOC01-APPB-T000002 
Figure JPOXMLDOC01-APPB-T000003
Abstract
Description
Oligosaccharide-containing composition
[0001] This invention relates to an oligosaccharide-containing composition.
[0002] Short-chain fatty acids produced by intestinal bacteria are among the most representative useful metabolites. Butyrate, in particular, has been reported to exhibit diverse effects, including improving inflammatory bowel disease and colorectal cancer, as well as immunomodulation and improving the intestinal barrier (Non-Patent Literature 1). Therefore, promoting the growth of butyrate-producing bacteria and butyrate production in the intestines is important for alleviating the symptoms of the above-mentioned diseases or maintaining good health.
[0003] As a technical means for promoting butyrate production, for example, Patent Document 1 discloses a composition for promoting intestinal butyrate production that contains inulin and cellulose.
[0004] Japanese Patent Publication No. 2020-130093
[0005] Singh V, et al., “Butyrate producers, “The Sentinel of Gut”: Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics.” Front Microbiol. 2023 Jan 12;13:1103836.
[0006] The object of this disclosure is to provide a novel composition that can promote butyrate production by butyrate-producing bacteria.
[0007] The present inventors have discovered that butyrate production is promoted by co-culturing butyrate-producing bacteria of the genus Faecalibacterium and Bifidobacterium bifidum in the presence of 2'-FL, 3'-SL, or 6'-SL and fructooligosaccharides, and have completed the present invention.
[0008] This disclosure relates to the following [1] to
[19] : [1] A composition comprising at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, and a fructooligosaccharide or a salt thereof. [2] The composition according to [1], wherein the oligosaccharide A is fucosyllactose and / or sialyl lactose. [3] The composition according to [1] or [2], wherein the oligosaccharide A is at least one oligosaccharide selected from the group consisting of 2'-fucosyllactose, 3'-sialyl lactose, and 6'-sialyl lactose. [4] The composition according to any one of [1] to [3], wherein the oligosaccharide A is 2'-fucosyllactose and / or 3'-sialyl lactose. [5] The composition according to any one of [1] to [4], wherein the oligosaccharide A is 2'-fucosyllactose. [6] The composition according to any one of [1] to [4], wherein the oligosaccharide A is 3'-sialyl lactose. [7] The composition according to any one of [1] to [3], wherein the oligosaccharide A is 6'-sialyl lactose. [8] The composition according to any one of [1] to [7], wherein the ratio of the content (mass%) of the oligosaccharide A or its salt, based on the total amount of the composition, to the content (mass%) of the fructooligosaccharide or its salt, based on the total amount of the composition, is 0.001 or more and 10 or less. [9] The composition according to any one of [1] to [8], wherein, if it contains 2'-fucosyl lactose, the ratio of the content of 2'-fucosyl lactose (by mass%) based on the total amount of the composition to the content of fructooligosaccharides (by mass%) based on the total amount of the composition is 0.01 or more and 0.3 or less; if it contains 3'-sialyl lactose, the ratio of the content of 3'-sialyl lactose (by mass%) based on the total amount of the composition to the content of fructooligosaccharides (by mass%) based on the total amount of the composition is 0.01 or more and 0.3 or less; and if it contains 6'-sialyl lactose, the ratio of the content of 6'-sialyl lactose (by mass%) based on the total amount of the composition to the content of fructooligosaccharides (by mass%) based on the total amount of the composition is 0.1 or more and 9 or less.
[10] The composition according to any one of [1] to [9], which is used in applications that utilize bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide.
[11] The composition according to
[10] , wherein the bacteria are capable of decomposing and assimilating the oligosaccharide A extracellularly. [12-0] The composition according to
[10] or
[11] , wherein the bacteria are one or more selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, and Akkermansia muciniphila.
[12] The composition according to
[10] ,
[11] , or [12-0], wherein the bacterium is Bifidobacterium bifidum. [12-1] The composition according to
[10] ,
[11] , or [12-0], wherein the bacterium is Bacteroides fragilis. [12-2] The composition according to
[10] ,
[11] , or [12-0], wherein the bacterium is Akkermansia muciniphila.
[13] The composition according to any one of [1] to [9], which is a composition for promoting butyrate production by butyrate-producing bacteria.
[14] The composition according to
[13] , wherein the butyrate-producing bacteria is a bacterium of the genus Faecalibacterium.
[15] The composition according to
[13] or
[14] , wherein the butyrate-producing bacterium is Faecalibacterium prausnitzii.
[16] The composition according to any one of
[13] to
[15] , wherein the butyrate production promotion is performed using a bacterium capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide.
[17] The composition according to
[16] , wherein the bacterium is capable of decomposing and assimilating the oligosaccharide A extracellularly.[18-0] The composition according to
[16] or
[17] , wherein the bacterium is one or more selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, and Akkermansia muciniphila.
[18] The composition according to
[16] ,
[17] , or [18-0], wherein the bacterium is Bifidobacterium bifidum. [18-1] The composition according to
[16] ,
[17] , or [18-0], wherein the bacterium is Bacteroides fragilis. [18-2] The composition according to
[16] ,
[17] , or [18-0], wherein the bacterium is Akkermansia muciniphila.
[19] The composition according to
[16] or
[17] , wherein the bacterium is capable of excreting the decomposition products of oligosaccharide A produced within the cell by an enzyme capable of decomposing oligosaccharide A.
[0009] The present disclosure also relates to the following [2-1] to [2-10]. [2-1] A composition containing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialyllated oligosaccharides, or a salt thereof, which is administered or ingested in combination with a fructooligosaccharide or a salt thereof. [2-2] A composition containing the fructooligosaccharide or a salt thereof, which is administered or ingested in combination with at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialyllated oligosaccharides, or a salt thereof. [2-3] The composition according to [2-1] or [2-2], wherein the oligosaccharide A is fucosyllactose and / or sialyllactose. [2-4] The composition according to any one of [2-1] to [2-3], wherein the oligosaccharide A is at least one oligosaccharide selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, and 6'-sialyllactose. [2-5] The composition according to any one of [2-1] to [2-4], wherein the oligosaccharide A is 2'-fucosyl lactose and / or 3'-sialyl lactose. [2-6] The composition according to any one of [2-1] to [2-5], wherein the oligosaccharide A is 2'-fucosyl lactose. [2-7] The composition according to any one of [2-1] to [2-5], wherein the oligosaccharide A is 3'-sialyl lactose. [2-8] The composition according to any one of [2-1] to [2-4], wherein the oligosaccharide A is 6'-sialyl lactose. [2-9] The composition according to any one of [2-1] to [2-8], wherein the ratio of the content (mass%) of the oligosaccharide A or its salt, based on the total amount of the composition, to the content (mass%) of the fructooligosaccharide or its salt, based on the total amount of the composition, is 0.001 or more and 10 or less.[2-10] The composition according to any one of [2-1] to [2-9], wherein the composition contains 2'-fucosyl lactose or a salt thereof, and the ratio of the content of fructooligosaccharides (mass%) to the total amount of the composition to the content of 2'-fucosyl lactose (mass%) to the total amount of the composition is 0.01 or more and 0.3 or less; the composition contains 3'-sialyl lactose, and the ratio of the content of fructooligosaccharides (mass%) to the total amount of the composition to the content of 3'-sialyl lactose (mass%) to the total amount of the composition is 0.01 or more and 0.3 or less; and the composition contains 6'-sialyl lactose, and the ratio of the content of fructooligosaccharides (mass%) to the total amount of the composition to the content of 6'-sialyl lactose (mass%) to the total amount of the composition is 0.1 or more and 9 or less.
[0010] This disclosure also relates to the following [3-1] to [3-41]. [3-1] A composition for use in applications using the bacteria, comprising as an active ingredient at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and a fructooligosaccharide or a salt thereof, and a bacterium capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide. [3-2] A composition for use in applications using the bacteria, comprising as an active ingredient a bacterium capable of decomposing and assimilating the oligosaccharide A or a salt thereof and the fructooligosaccharide or a salt thereof. [3-3] A bacterium capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, and a composition for use in applications using the bacterium, which contains the oligosaccharide A or a salt thereof as an active ingredient and is administered or ingested in combination with the oligosaccharide A or a salt thereof. [3-4] A bacterium capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, and a composition for use in applications using the bacterium, which contains the oligosaccharide A or a salt thereof as an active ingredient and is administered or ingested in combination with the oligosaccharide A or a salt thereof. [3-5] A composition for use in applications using the bacteria, comprising an oligosaccharide A or a salt thereof, and a fructooligosaccharide or a salt thereof, as active ingredients, which is administered or ingested in combination with bacteria capable of decomposing and utilizing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides. [3-6] A composition for use in applications using the bacteria, comprising an active ingredient, which is administered or ingested in combination with at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and a fructooligosaccharide or a salt thereof, which is capable of decomposing and utilizing the oligosaccharide A and / or fructooligosaccharides.[3-7] Use of the oligosaccharide A or a salt thereof, the fructooligosaccharide or a salt thereof, and the bacteria for producing a composition for use in applications that utilize bacteria capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides. [3-8] Use of the oligosaccharide A or a salt thereof, and the fructooligosaccharide or a salt thereof, for producing a composition for use in applications that utilize the bacteria, using bacteria capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides. [3-9] Use of the bacteria for producing a composition for use in applications that utilize bacteria capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides. [3-10] Use of the oligosaccharide A or a salt thereof for producing a composition for use in applications employing the bacteria, which is administered or ingested in combination with the oligosaccharide A or a salt thereof, and which is selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, and which is selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, and which is administered or ingested in combination with the oligosaccharide A or a salt thereof. [3-11] Use of the fructooligosaccharide or a salt thereof for producing a composition for use in applications employing the bacteria, which is selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, and which is administered or ingested in combination with the oligosaccharide A or a salt thereof. [3-12] Use of oligosaccharide A or a salt thereof, and fructooligosaccharide or a salt thereof, for the production of a composition for use in applications using the bacteria, which is administered or ingested in combination with bacteria capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides.[3-13] Use of the bacteria for producing a composition for use in applications using bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide, which is administered or ingested in combination with at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sially modified oligosaccharides, and fructooligosaccharide or a salt thereof. [3-14] Use of the oligosaccharide A or a salt thereof and the fructooligosaccharide or a salt thereof for use in applications using bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide, selected from the group consisting of fucosylated oligosaccharides and sially modified oligosaccharides. [3-15] Use of the bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide, using at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sially modified oligosaccharides, and fructooligosaccharide or a salt thereof, for use in applications using bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide. [3-16] Oligosaccharide A or a salt thereof for use in a therapeutic method using bacteria capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, wherein the oligosaccharide A or a salt thereof is administered or ingested in combination with the bacteria and the fructooligosaccharide or a salt thereof. [3-17] Fructooligosaccharide or a salt thereof for use in a therapeutic method using bacteria capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, wherein the fructooligosaccharide or a salt thereof is administered or ingested in combination with the bacteria and the oligosaccharide A or a salt thereof. [3-18] A composition for use in a therapeutic method using bacteria capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, the composition containing the oligosaccharide A or a salt thereof and the fructooligosaccharide or a salt thereof, which is administered or ingested in combination with the bacteria.[3-19] A bacterium capable of decomposing and assimilating at least one oligosaccharide A and / or fructooligosaccharide selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, for use in a therapeutic method using a bacterium capable of decomposing and assimilating at least one oligosaccharide A and / or fructooligosaccharide selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, wherein the bacterium is administered or ingested in combination with the oligosaccharide A or a salt thereof and the fructooligosaccharide or a salt thereof. [3-20] Use of the oligosaccharide A or a salt thereof in a non-therapeutic method using a bacterium capable of decomposing and assimilating at least one oligosaccharide A and / or fructooligosaccharide selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, wherein the bacterium is administered or ingested in combination with the oligosaccharide A and / or fructooligosaccharide or a salt thereof. [3-21] Use of fructooligosaccharide or a salt thereof in a non-therapeutic method using bacteria capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, wherein the bacteria and the oligosaccharide A or salt thereof are administered or ingested in combination. [3-22] Use of a composition containing oligosaccharide A or a salt thereof and fructooligosaccharide or a salt thereof in a non-therapeutic method using bacteria capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, wherein the bacteria and the composition are administered or ingested in combination. [3-23] Use of a bacterium in a non-therapeutic method using a bacterium capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, wherein the bacterium is administered or ingested in combination with the oligosaccharide A or a salt thereof and the fructooligosaccharide or a salt thereof.[3-24] A method for treating a disease that can be treated using the bacteria, or a method for promoting health that yields an improvement effect, comprising the step of administering or ingesting at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof, fructooligosaccharide or a salt thereof, and bacteria that can decompose and utilize the oligosaccharide A and / or fructooligosaccharide. [3-25] A method for treating a disease that can be treated using the bacteria that can decompose and utilize the oligosaccharide A and / or fructooligosaccharide, or a method for promoting health that yields an improvement effect, comprising the step of administering or ingesting at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof, and fructooligosaccharide or a salt thereof. [3-26] A composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [3-1] to [3-25], wherein the oligosaccharide A is fucosyllactose and / or sialyllactose. [3-27] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [3-1] to [3-26], wherein the oligosaccharide A is at least one oligosaccharide selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, and 6'-sialyllactose. [3-28] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [3-1] to [3-27], wherein the oligosaccharide A is 2'-fucosyllactose and / or 3'-sialyllactose. [3-29] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [3-1] to [3-28], wherein the oligosaccharide A is 2'-fucosyllactose. [3-30] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [3-1] to [3-28], wherein the oligosaccharide A is 3'-sialyl lactose. [3-31] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [3-1] to [3-27], wherein the oligosaccharide A is 6'-sialyl lactose.[3-32] The composition or use according to any one of [3-1] to [3-13] and [3-26] to [3-31], wherein the ratio of the content (mass%) of oligosaccharide A or its salt, based on the total amount of the composition, to the content (mass%) of fructooligosaccharide or its salt, based on the total amount of the composition, is 0.001 or more and 10 or less. [3-33] The composition, use, oligosaccharide A or its salt, fructooligosaccharide or its salt, bacteria, and method according to any one of [3-2] to [3-31], wherein the ratio of the dose or intake of oligosaccharide A or its salt, based on the total amount of the composition, to the dose or intake of fructooligosaccharide or its salt, is 0.001 or more and 10 or less. [3-34] If the composition contains 2'-fucosyl lactose or a salt thereof, the ratio of the content of fructooligosaccharides (mass%) to the total amount of the composition to the content of 2'-fucosyl lactose (mass%) to the total amount of the composition is 0.01 or more and 0.3 or less. If the composition contains 3'-sialyl lactose, the ratio of the content of fructooligosaccharides (mass%) to the total amount of the composition to the content of 3'-sialyl lactose (mass%) to the total amount of the composition is 0.01 or more and 0.3 or less. If the composition contains 6'-sialyl lactose, the ratio of the content of fructooligosaccharides (mass%) to the total amount of the composition to the content of 6'-sialyl lactose (mass%) to the total amount of the composition is 0.1 or more and 9 or less. The composition or use according to any one of [3-1] to [3-13] and [3-26] to [3-32].[3-35] When administering or allowing a subject to ingest 2'-fucosyl lactose, the ratio of the amount of fructooligosaccharide administered or ingested to the amount of 2'-fucosyl lactose administered or ingested is 0.01 or more and 0.3 or less. When administering or allowing a subject to ingest 3'-sialyl lactose, the ratio of the amount of fructooligosaccharide administered or ingested to the amount of 3'-sialyl lactose administered or ingested is 0.01 or more and 0.3 or less. When administering or allowing a subject to ingest 6'-sialyl lactose, the ratio of the amount of fructooligosaccharide administered or ingested to the amount of 6'-sialyl lactose administered or ingested is 0.1 or more and 9 or less. The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method described in any of [3-2] to [3-31] and [3-33]. [3-36] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [3-1] to [3-35], wherein the bacteria are bacteria capable of decomposing and assimilating the oligosaccharide A outside the cell. [3-37-0] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [3-1] to [3-36], wherein the bacteria are one or more selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, and Akkermansia muciniphila. [3-37] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [3-1] to [3-36] and [3-37-0], wherein the bacterium is Bifidobacterium bifidum. [3-37-1] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [3-1] to [3-36] and [3-37-0], wherein the bacterium is Bacteroides fragilis.[3-37-2] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [3-1] to [3-36] and [3-37-0], wherein the bacterium is Akkermansia muciniphila. [3-38] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [3-1] to [3-36], wherein the bacterium is a bacterium that can excrete the decomposition products of oligosaccharide A produced inside the cell by an enzyme that can decompose oligosaccharide A. [3-39] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [3-1] to [3-38], wherein the use of the bacterium is for promoting butyrate production by butyrate-producing bacteria. [3-40] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to [3-39], wherein the butyrate-producing bacteria is a bacterium of the genus Faecalibacterium. [3-41] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to [3-39] or [3-40], wherein the butyrate-producing bacteria is Faecalibacterium prausnitzii.
[0011] This disclosure also relates to the following [4-1] to [4-31]. [4-1] A composition for promoting butyrate production in butyrate-producing bacteria, containing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof, and a fructooligosaccharide or a salt thereof as active ingredients. [4-2] A composition for promoting butyrate production in butyrate-producing bacteria, containing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof as an active ingredient, which is administered or ingested in combination with a fructooligosaccharide or a salt thereof. [4-3] A composition for promoting butyrate production in butyrate-producing bacteria, containing a fructooligosaccharide or a salt thereof as an active ingredient, which is administered or ingested in combination with at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof. [4-4] Use of at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, and fructooligosaccharide or a salt thereof, for the production of a composition for promoting butyrate production in butyrate-producing bacteria. [4-5] Use of at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, for the production of a composition for promoting butyrate production in butyrate-producing bacteria, which is administered or ingested in combination with fructooligosaccharide or a salt thereof. [4-6] Use of the fructooligosaccharide or a salt thereof, for the production of a composition for promoting butyrate production in butyrate-producing bacteria, which is administered or ingested in combination with at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof. [4-7] Use of at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, and fructooligosaccharide or a salt thereof, for use in promoting butyrate production in butyrate-producing bacteria. [4-8] Oligosaccharide A or a salt thereof, selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, for use in therapeutic methods to promote butyrate production by butyrate-producing bacteria, wherein the oligosaccharide A or a salt thereof is administered or ingested in combination with a fructooligosaccharide or a salt thereof.[4-9] A fructooligosaccharide or a salt thereof for use in a therapeutic method to promote butyrate production by butyrate-producing bacteria, which is administered or ingested in combination with at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides. [4-10] Use in a non-therapeutic method to promote butyrate production by butyrate-producing bacteria, which is administered or ingested in combination with the fructooligosaccharide or a salt thereof. [4-11] Use in a non-therapeutic method to promote butyrate production by butyrate-producing bacteria, which is administered or ingested in combination with at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides. [4-12] A method for treating a disease that can be treated by promoting butyrate production by butyrate-producing bacteria, or a method for promoting health that can obtain an improvement effect, comprising the step of administering or ingesting at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and siallylated oligosaccharides, and fructooligosaccharide or a salt thereof. [4-13] A method for producing butyrate, comprising the step of acting on butyrate-producing bacteria with at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and siallylated oligosaccharides, and fructooligosaccharide or a salt thereof. [4-14] A method for increasing butyrate-producing bacteria, comprising the step of acting on butyrate-producing bacteria with at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and siallylated oligosaccharides, and fructooligosaccharide or a salt thereof. [4-15] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to any one of [4-1] to [4-14], wherein the oligosaccharide A is fucosyl lactose and / or sialyl lactose. [4-16] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to any one of [4-1] to [4-15], wherein the oligosaccharide A is at least one oligosaccharide selected from the group consisting of 2'-fucosyl lactose, 3'-sialyl lactose, and 6'-sialyl lactose.[4-17] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to any one of [4-1] to [4-16], wherein the oligosaccharide A is 2'-fucosyl lactose and / or 3'-sialyl lactose. [4-18] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to any one of [4-1] to [4-17], wherein the oligosaccharide A is 2'-fucosyl lactose. [4-19] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to any one of [4-1] to [4-17], wherein the oligosaccharide A is 3'-sialyl lactose. [4-20] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to any one of [4-1] to [4-16], wherein the oligosaccharide A is 6'-sialyl lactose. [4-21] The composition or use according to any one of [4-1] to [4-6] and [4-15] to [4-20], wherein the ratio of the content (mass%) of oligosaccharide A or its salt, based on the total amount of the composition, to the content (mass%) of fructooligosaccharide or its salt, based on the total amount of the composition, is 0.001 or more and 10 or less. [4-22] The composition, use, oligosaccharide A or its salt, fructooligosaccharide or its salt, or method according to any one of [4-2] to [4-20], wherein the ratio of the amount administered or ingested of oligosaccharide A or its salt, based on the total amount of the composition, to the amount administered or ingested of fructooligosaccharide or its salt, is 0.001 or more and 10 or less.[4-23] If the composition contains 2'-fucosyl lactose or a salt thereof, the ratio of the content of fructooligosaccharides (mass%) to the total amount of the composition to the content of 2'-fucosyl lactose (mass%) to the total amount of the composition is 0.01 or more and 0.3 or less. If the composition contains 3'-sialyl lactose, the ratio of the content of fructooligosaccharides (mass%) to the total amount of the composition to the content of 3'-sialyl lactose (mass%) to the total amount of the composition is 0.01 or more and 0.3 or less. If the composition contains 6'-sialyl lactose, the ratio of the content of fructooligosaccharides (mass%) to the total amount of the composition to the content of 6'-sialyl lactose (mass%) to the total amount of the composition is 0.1 or more and 9 or less. The composition or use according to any of [4-1] to [4-6] and [4-15] to [4-21]. [4-24] When administering or allowing a subject to ingest 2'-fucosyl lactose, the ratio of the amount of fructooligosaccharide administered or ingested to the amount of 2'-fucosyl lactose administered or ingested is 0.01 or more and 0.3 or less. When administering or allowing a subject to ingest 3'-sialyl lactose, the ratio of the amount of fructooligosaccharide administered or ingested to the amount of 3'-sialyl lactose administered or ingested is 0.01 or more and 0.3 or less. When administering or allowing a subject to ingest 6'-sialyl lactose, the ratio of the amount of fructooligosaccharide administered or ingested to the amount of 6'-sialyl lactose administered or ingested is 0.1 or more and 9 or less. The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to any one of [4-2] to [4-20] and [4-22]. [4-25] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to any one of [4-1] to [4-24], wherein the butyrate-producing bacterium is a bacterium of the genus Faecalibacterium. [4-26] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to [4-25], wherein the butyrate-producing bacterium is Faecalibacterium prausnitzii.[4-27] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to any one of [4-1] to [4-26], wherein the butyrate production promotion is performed using bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide. [4-28] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to [4-27], wherein the bacteria are bacteria capable of decomposing and assimilating the oligosaccharide A outside the cell. [4-29-0] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to [4-27] or [4-28], wherein the bacterium is one or more selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, and Akkermansia muciniphila. [4-29] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to [4-27], [4-28], or [4-29-0], wherein the bacterium is Bifidobacterium bifidum. [4-29-1] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to [4-27], [4-28], or [4-29-0], wherein the bacterium is Bacteroides fragilis. [4-29-2] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to [4-27], [4-28], or [4-29-0], wherein the bacterium is Akkermansia muciniphylla. [4-30] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and method according to [4-27] or [4-28], wherein the bacterium is a bacterium that can excrete the decomposition products of oligosaccharide A produced inside the cell by an enzyme capable of decomposing oligosaccharide A.
[0012] This disclosure also relates to the following [5-1] to [5-43]. [5-1] A composition for promoting butyrate production by butyrate-producing bacteria, comprising as an active ingredient at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof, a fructooligosaccharide or a salt thereof, and a bacterium capable of decomposing and utilizing the oligosaccharide A and / or the fructooligosaccharide. [5-2] A composition for promoting butyrate production by butyrate-producing bacteria, comprising as an active ingredient at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or a bacterium capable of decomposing and utilizing the fructooligosaccharide. [5-3] A composition for promoting butyrate production in butyrate-producing bacteria, comprising at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and / or bacteria capable of decomposing and utilizing the fructooligosaccharide, and the oligosaccharide A or a salt thereof as an active ingredient, administered or ingested in combination with the fructooligosaccharide or a salt thereof. [5-4] A composition for promoting butyrate production in butyrate-producing bacteria, comprising at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and / or bacteria capable of decomposing and utilizing the fructooligosaccharide, and the fructooligosaccharide or a salt thereof as an active ingredient, administered or ingested in combination with the oligosaccharide A or a salt thereof. [5-5] A composition for promoting butyrate production in butyrate-producing bacteria, comprising at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and siallylated oligosaccharides, and / or a bacterium capable of decomposing and utilizing the fructooligosaccharide, administered or ingested in combination with the oligosaccharide A or a salt thereof, and the fructooligosaccharide or a salt thereof as active ingredients. [5-6] A composition for promoting butyrate production in butyrate-producing bacteria, comprising at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and siallylated oligosaccharides, and a salt thereof, administered or ingested in combination with the fructooligosaccharide or a salt thereof, and a bacterium capable of decomposing and utilizing the oligosaccharide A and / or the fructooligosaccharide as active ingredients.[5-7] Use of at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof, fructooligosaccharide or a salt thereof, and bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide, for the production of a composition for promoting butyrate production by butyrate-producing bacteria. [5-8] Use of the oligosaccharide A or a salt thereof and the fructooligosaccharide or a salt thereof for the production of a composition for promoting butyrate production by butyrate-producing bacteria using at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and bacteria capable of decomposing and assimilating the fructooligosaccharide. [5-9] Use of bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide, for the production of a composition for promoting butyrate production by butyrate-producing bacteria using at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof. [5-10] Use of oligosaccharide A or a salt thereof to produce a composition for promoting butyrate production in butyrate-producing bacteria, which is administered or ingested in combination with bacteria that can decompose and utilize at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, and oligosaccharide A or a salt thereof. [5-11] Use of fructooligosaccharide or a salt thereof to produce a composition for promoting butyrate production in butyrate-producing bacteria, which is administered or ingested in combination with bacteria that can decompose and utilize at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, and oligosaccharide A or a salt thereof. [5-12] Use of oligosaccharide A or a salt thereof and fructooligosaccharide or a salt thereof for producing a composition for promoting butyrate production of butyrate-producing bacteria, which is administered or ingested in combination with bacteria capable of decomposing and utilizing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides.[5-13] Use of bacteria capable of decomposing and assimilating oligosaccharide A and / or fructooligosaccharide for the production of a composition for promoting butyrate production of butyrate-producing bacteria, which is administered or ingested in combination with at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and siallylated oligosaccharides and fructooligosaccharide or a salt thereof. [5-14] Oligosaccharide A or a salt thereof, and fructooligosaccharide or a salt thereof, for use in promoting butyrate production of butyrate-producing bacteria using bacteria capable of decomposing and assimilating at least one oligosaccharide A and / or fructooligosaccharide selected from the group consisting of fucosylated oligosaccharides and siallylated oligosaccharides. [5-15] Bacteria capable of decomposing and assimilating oligosaccharide A and / or fructooligosaccharide for use in promoting butyrate production of butyrate-producing bacteria using at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and siallylated oligosaccharides, and fructooligosaccharide or a salt thereof. [5-16] Oligosaccharide A or a salt thereof, selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, for use in a therapeutic method to promote butyrate production by butyrate-producing bacteria, wherein the oligosaccharide A or a salt thereof is administered or ingested in combination with bacteria capable of decomposing and assimilating the oligosaccharide A and / or fructooligosaccharides, and the oligosaccharide A or a salt thereof. [5-17] Fructooligosaccharide or a salt thereof, for use in a therapeutic method to promote butyrate production by butyrate-producing bacteria, wherein the oligosaccharide A or a salt thereof is administered or ingested in combination with bacteria capable of decomposing and assimilating the oligosaccharide A and / or fructooligosaccharides, selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and the oligosaccharide A or a salt thereof. [5-18] A composition for use in a therapeutic method to promote butyrate production by butyrate-producing bacteria, comprising at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, and a fructooligosaccharide or a salt thereof, which is administered or ingested in combination with bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide.[5-19] A bacterium capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, for use in a therapeutic method to promote butyrate production by butyrate-producing bacteria, wherein the bacterium is administered or ingested in combination with the oligosaccharide A or a salt thereof and the fructooligosaccharide or a salt thereof. [5-20] Use in a non-therapeutic method to promote butyrate production by butyrate-producing bacteria, wherein the bacterium is administered or ingested in combination with the oligosaccharide A or a salt thereof, selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, wherein the bacterium is administered or ingested in combination with the oligosaccharide A or a salt thereof. [5-21] Use of fructooligosaccharides or salts thereof in a non-therapeutic method for promoting butyrate production by butyrate-producing bacteria, wherein the fructooligosaccharides or salts thereof are administered or ingested in combination with at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or bacteria capable of decomposing and utilizing the fructooligosaccharides, and the oligosaccharides A or salts thereof. [5-22] Use of a composition containing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, and fructooligosaccharides or salts thereof in a non-therapeutic method for promoting butyrate production by butyrate-producing bacteria, wherein the composition is administered or ingested in combination with bacteria capable of decomposing and utilizing the oligosaccharides A and / or fructooligosaccharides. [5-23] Use of bacteria capable of decomposing and assimilating at least one oligosaccharide A and / or fructooligosaccharide selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, in a non-therapeutic method for promoting butyrate production by butyrate-producing bacteria, wherein the bacteria are administered or ingested in combination with the oligosaccharide A or a salt thereof and the fructooligosaccharide or a salt thereof.[5-24] A method for treating a disease that can be treated by promoting butyrate production by butyrate-producing bacteria, or a method for promoting health that can obtain an improvement effect, comprising the step of administering or ingesting at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and siallylated oligosaccharides, fructooligosaccharide or a salt thereof, and bacteria that can decompose and utilize the oligosaccharide A and / or fructooligosaccharide. [5-25] A method for treating a disease that can be treated by promoting butyrate production by butyrate-producing bacteria, or a method for promoting health that can obtain an improvement effect, comprising the step of administering at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and siallylated oligosaccharides, and fructooligosaccharide or a salt thereof, using bacteria that can decompose and utilize the oligosaccharide A and / or fructooligosaccharide. [5-26] A method for producing butyric acid, comprising the step of acting on bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide, and butyrate-producing bacteria, with at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and a fructooligosaccharide or a salt thereof. [5-27] A method for producing butyric acid, comprising the step of acting on butyrate-producing bacteria with at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, a fructooligosaccharide or a salt thereof, and bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide. [5-28] A method for growing butyrate-producing bacteria, comprising the step of acting on butyrate-producing bacteria with at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof, a fructooligosaccharide or a salt thereof, and bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide. [5-29] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [5-1] to [5-28], wherein the oligosaccharide A is fucosyllactose and / or sialyllactose. [5-30] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [5-1] to [5-29], wherein the oligosaccharide A is at least one oligosaccharide selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, and 6'-sialyllactose.[5-31] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [5-1] to [5-30], wherein the oligosaccharide A is 2'-fucosyl lactose and / or 3'-sialyl lactose. [5-32] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [5-1] to [5-31], wherein the oligosaccharide A is 2'-fucosyl lactose. [5-33] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [5-1] to [5-31], wherein the oligosaccharide A is 3'-sialyl lactose. [5-34] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [5-1] to [5-30], wherein the oligosaccharide A is 6'-sialyl lactose. [5-35] The composition or use according to any one of [5-1] to [5-13] and [5-29] to [5-34], wherein the ratio of the content (mass%) of oligosaccharide A or a salt thereof, based on the total amount of the composition, to the content (mass%) of fructooligosaccharide or a salt thereof, based on the total amount of the composition, is 0.001 or more and 10 or less. [5-36] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [5-2] to [5-34], wherein the ratio of the dose or intake of oligosaccharide A or a salt thereof, based on the total amount of the composition, to the dose or intake of fructooligosaccharide or a salt thereof, is 0.001 or more and 10 or less.[5-37] If the composition contains 2'-fucosyl lactose or a salt thereof, the ratio of the content of fructooligosaccharides (mass%) to the total amount of the composition to the content of 2'-fucosyl lactose (mass%) to the total amount of the composition is 0.01 or more and 0.3 or less. If the composition contains 3'-sialyl lactose, the ratio of the content of fructooligosaccharides (mass%) to the total amount of the composition to the content of 3'-sialyl lactose (mass%) to the total amount of the composition is 0.01 or more and 0.3 or less. If the composition contains 6'-sialyl lactose, the ratio of the content of fructooligosaccharides (mass%) to the total amount of the composition to the content of 6'-sialyl lactose (mass%) to the total amount of the composition is 0.1 or more and 9 or less. The composition or use according to any one of [5-1] to [5-13] and [5-29] to [5-35]. [5-38] When administering or allowing a subject to ingest 2'-fucosyl lactose, the ratio of the amount of fructooligosaccharide administered or ingested to the amount of 2'-fucosyl lactose administered or ingested is 0.01 or more and 0.3 or less. When administering or allowing a subject to ingest 3'-sialyl lactose, the ratio of the amount of fructooligosaccharide administered or ingested to the amount of 3'-sialyl lactose administered or ingested is 0.01 or more and 0.3 or less. When administering or allowing a subject to ingest 6'-sialyl lactose, the ratio of the amount of fructooligosaccharide administered or ingested to the amount of 6'-sialyl lactose administered or ingested is 0.1 or more and 9 or less. The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method described in any of [5-2] to [5-34] and [5-36]. [5-39] The bacterium is a bacterium capable of decomposing and assimilating the oligosaccharide A outside the cell, the composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacterium, and method according to any one of [5-1] to [5-38].[5-40-0] The composition, use, the oligosaccharide A or a salt thereof, the fructooligosaccharide or a salt thereof, the bacteria, and the method according to any one of [5-1] to [5-38], wherein the bacteria is one or more selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, and Akkermansia muciniphylla. [5-40] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [5-1] to [5-38] and [5-40-0], wherein the bacterium is Bifidobacterium bifidum. [5-40-1] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [5-1] to [5-38] and [5-40-0], wherein the bacterium is Bacteroides fragilis. [5-40-2] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [5-1] to [5-38] and [5-40-0], wherein the bacterium is Akkermansia muciniphila. [5-41] The composition according to any one of [5-1] to [5-39], wherein the bacterium is a bacterium capable of excreting the decomposition products of oligosaccharide A produced inside the cell by an enzyme capable of decomposing oligosaccharide A. [5-42] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to any one of [5-1] to [5-41], wherein the butyrate-producing bacterium is a bacterium of the genus Faecalibacterium. [5-43] The composition, use, oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, bacteria, and method according to [5-42], wherein the butyrate-producing bacterium is Faecalibacterium prausnitzii.
[0013] According to this disclosure, it is possible to provide a novel composition that can promote butyrate production by butyrate-producing bacteria.
[0014] 2' - This graph shows the butyrate concentration in the culture supernatant when Faecalibacterium prausnizzi JCM31915 and Bifidobacterium bifidum JCM1254 are co-cultured while varying the ratio of FL content and fructooligosaccharide content. 3' - This graph shows the butyrate concentration in the culture supernatant when Faecalibacterium prausnizzi JCM31915 and Bifidobacterium bifidum JCM1254 are co-cultured while varying the ratio of SL content and fructooligosaccharide content. 6' - This graph shows the butyrate concentration in the culture supernatant when Faecalibacterium prausnizzi JCM31915 and Bifidobacterium bifidum JCM1254 are co-cultured while varying the ratio of SL content and fructooligosaccharide content. This graph shows the butyric acid concentration in the culture supernatant when Faecalibacterium prausnizzi JCM31915 and Bifidobacterium bifidum JCM1254 are co-cultured while varying the ratio of 2'-FL content and fructooligosaccharide content. This graph shows the butyric acid concentration in the culture supernatant when Faecalibacterium prausnizzi JCM31915 and Bacteroides fragilis JCM17586 are co-cultured while varying the ratio of 2'-FL content and fructooligosaccharide content. This graph shows the butyric acid concentration in the culture supernatant when Faecalibacterium prausnizzi JCM31915 and Akkermansia muciniphylla JCM30893 are co-cultured while varying the ratio of 2'-FL content and fructooligosaccharide content.
[0015] The following describes in detail embodiments for carrying out the present invention. However, the present invention is not limited to the following embodiments.
[0016] The composition according to this embodiment contains at least one oligosaccharide selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides (also referred to as "oligosaccharide A" in this specification) or a salt thereof, and a fructooligosaccharide or a salt thereof.
[0017] In this disclosure, "fucosylated oligosaccharide" refers to an oligosaccharide substituted with at least one fucose molecule, and includes fucosylsucrose, fucosyllactose (FL), difucosyllactose (DF-L or LDFT), fucosylmaltose, fucosyllactulose, fucosyltrehalose, fucosyllactosucrose, and fucosylraffinose, but preferably fucosyllactose.
[0018] Examples of fucosyl lactose include 2'-fucosyl lactose (2'-FL), 3-fucosyl lactose (3-FL), and 2',3-difucosyl lactose, with 2'-FL being preferred.
[0019] In this disclosure, "sially modified oligosaccharide" refers to an oligosaccharide substituted with at least one sialic acid, such as sialyl lactose (SL).
[0020] Examples of sialyl lactose include 3'-sialyl lactose (3'-SL) and 6'-sialyl lactose (6'-SL).
[0021] Salts that can be formed from fucosylated oligosaccharides and sialylated oligosaccharides include pharmaceutically acceptable salts, more specifically, acid addition salts, metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts. Examples of acid addition salts include inorganic salts such as hydrochloride, sulfate, nitrate, and phosphate, as well as organic salts such as acetate, maleate, fumarate, citrate, malate, lactate, α-ketoglutarate, and gluconate and caprylate. Examples of metal salts include alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as magnesium and calcium salts, aluminum salts, and zinc salts. Examples of ammonium salts include salts with ammonium and tetramethylammonium. Examples of organic amine addition salts include salts with morpholine and piperidine. Examples of amino acid addition salts include salts with glycine, phenylalanine, lysine, aspartic acid, and glutamic acid. Of the salts mentioned above, SL is preferably a sodium salt, but other salts or two or more salts may be used in appropriate combinations.
[0022] At least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides is the above-mentioned oligosaccharide A or a salt thereof, preferably at least one oligosaccharide or a salt thereof selected from the group consisting of fucosyllactose and sialyllactose, and more preferably at least one oligosaccharide or a salt thereof selected from the group consisting of 2'-FL, 3'-SL, and 6'-SL. In another embodiment, oligosaccharide A or a salt thereof may be 2'-FL and / or 3'-SL, or it may be 2'-FL, it may be 3'-SL, or it may be 6'-SL.
[0023] Fucosylated oligosaccharides or sialized oligosaccharides or salts thereof can be produced by known methods. For example, 3'-SL or a salt thereof can be produced by the method described in International Publication No. 2017 / 195743, and 6'-SL or a salt thereof can be produced by the method described in International Publication No. 2017 / 086443.
[0024] In this disclosure, "fructooligosaccharide" is a general term for oligosaccharides in which one to three molecules of fructose are bonded to a fructose residue of sucrose via β-1,2 links, and includes the trisaccharides 1-kestose, 6-kestose, and neokestose, the tetrasaccharide nistose, and the pentasaccharide 1-fructosylnistose. Fructooligosaccharides may be used individually or in combination of two or more types. Specifically, the fructooligosaccharide may be at least one selected from the group consisting of 1-kestose, 6-kestose, neokestose, nistose, and 1-fructosylnistose, and may contain 1-kestose, nistose, and 1-fructofuranosylnistose (1-fructofuranosyl-D-nistose), or may be a mixture of 1-kestose, nistose, and 1-fructofuranosylnistose (1-fructofuranosyl-D-nistose). The salts that the fructooligosaccharide can form may be the same as the salts that the fucosylated oligosaccharide described above can form.
[0025] Fructooligosaccharides or salts thereof can be produced by known methods. For example, they can be produced by the method described in International Publication No. 2015 / 068764. Alternatively, purified fructooligosaccharides or salts thereof may be used, or commercially available compositions for food or reagent use may be used. Examples of commercially available compositions include a mixture of 1-kestose, nystose, and 1-fructofuranosyl-D-nystose (fructooligosaccharides manufactured by Fujifilm Wako Pure Chemical Industries, Ltd. (catalog number 062-02381)).
[0026] In this disclosure, "active ingredient" refers to an ingredient that exhibits the effect intended for its administration or ingestion. This effect may be, for example, brought about by bacteria capable of breaking down and utilizing the above-mentioned oligosaccharide A and / or fructooligosaccharide, ultimately resulting in the promotion of butyrate production itself, or effects brought about by such promotion. For example, in pharmaceuticals, active ingredients are administered to patients for the purpose of treating diseases, alleviating symptoms, or preventing recurrence, and their effects are described on the label or in the accompanying leaflet. In addition, in health foods (including foods with health claims, foods with functional claims, enteral nutrition foods, foods for special dietary uses, foods with nutritional function claims, foods for specified health uses, or nutritional supplements), active ingredients are ingested for the purpose of exhibiting specific effects that are particularly useful in maintaining and promoting the health of healthy individuals, and their effects are described on the packaging of the food. In other words, active ingredients may be used for therapeutic purposes or for non-therapeutic purposes. The effects brought about by bacteria capable of decomposing and utilizing the above-mentioned oligosaccharide A and / or fructooligosaccharide, and the butyrate production-promoting effect, may be obtained for therapeutic purposes or for non-therapeutic purposes unless otherwise specified.
[0027] "Therapeutic purpose" may refer to a concept that includes, for example, medical procedures, and more specifically, a concept that includes treatments performed on the human body.
[0028] "Non-therapeutic purposes" may refer to a concept that does not include medical procedures, and more specifically, a concept that does not include treatment of the human body. Examples of non-therapeutic purposes include health promotion or cosmetic purposes.
[0029] The composition according to this embodiment may be used, for example, in applications that utilize bacteria capable of decomposing and utilizing the above-mentioned oligosaccharide A and / or fructooligosaccharide.
[0030] In this disclosure, "assimilation" means that a microorganism utilizes the above-mentioned oligosaccharide A and / or fructooligosaccharide as a nutrient source. This includes the growth of the microorganism by directly taking in oligosaccharide A and / or fructooligosaccharide or by decomposing and taking it in outside the cell. Whether or not oligosaccharide A and / or fructooligosaccharide are assimilated by a microorganism can be determined by whether or not the amount of oligosaccharide A and / or fructooligosaccharide present before assimilation decreases or disappears after assimilation. The decrease or disappearance of oligosaccharide A and / or fructooligosaccharide can be evaluated, for example, by high-performance liquid chromatography (HPLC), ion chromatography (IC), and mass spectrometry (MS).
[0031] Bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharides may, for example, be bacteria capable of decomposing and utilizing oligosaccharide A. Examples of bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharides include Bifidobacteria (Bifidobacterium genus bacteria) capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharides, Bacteroides genus bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharides, and Akkermansia genus bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharides. Preferably, Bifidobacteria (Bifidobacterium genus bacteria) capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharides are used, and more preferably, Bifidobacterium bifidum is used. Examples of Bifidobacterium bifidum include Bifidobacterium bifidum JCM1254.
[0032] Examples of Bacteroides bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharides include Bacteroides fragilis (or B. fragilis) and Bacteroides thetaiotaomicron (or B. thetaiotaomicron). An example of Bacteroides fragilis is Bacteroides fragilis JCM17586.
[0033] Examples of Akkermansia bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharides include Akkermansia muciniphylla (or A. muciniphylla). An example of Akkermansia muciniphylla is Akkermansia muciniphylla JCM30893.
[0034] In another embodiment, the bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharide may be at least one selected from the group consisting of Bifidobacterium (bifidobacterium genus bacteria) capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharide, Bacteroides (bacteroides genus bacteria) capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharide, and Akkermansia (Akkermansia genus bacteria) capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharide; more preferably, at least one selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, and Akkermansia muciniphila; even more preferably, Bifidobacterium bifidum JCM1254, Bacteroides fragilis It is at least one species selected from the group consisting of JCM17586 and Ackermansia muciniphylla JCM30893.
[0035] In this disclosure, the use of bacteria capable of decomposing and utilizing the above-mentioned oligosaccharide A and / or fructooligosaccharide is any use brought about by the action of the bacteria, and the use of bacteria capable of decomposing and utilizing the above-mentioned oligosaccharide A and / or fructooligosaccharide may be any use brought about by administering or ingesting a combination of "oligosaccharide A and fructooligosaccharide" and bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharide. Examples of uses of bacteria capable of decomposing and utilizing the above-mentioned oligosaccharide A and / or fructooligosaccharide include promoting butyrate production by butyrate-producing bacteria, regulating pH in the intestines, supplying energy to intestinal epithelial cells, suppressing inflammation, regulating immunity, and improving the intestinal barrier. The action brought about by using bacteria capable of decomposing and utilizing the above-mentioned oligosaccharide A and / or fructooligosaccharide may provide an improvement effect on a predetermined disease or predetermined function. Therefore, this disclosure also provides a therapeutic agent or method for treating the above-mentioned disease that can be treated by the action brought about by using bacteria that can decompose and utilize the above-mentioned oligosaccharide A and / or the above-mentioned fructooligosaccharide, and a composition for improving the above-mentioned disease or a method for promoting health that can obtain the above-mentioned improvement effect. These methods will be described later.
[0036] In this disclosure, the bacteria capable of degrading and utilizing the above-mentioned oligosaccharide A and / or fructooligosaccharide may also be bacteria capable of degrading and utilizing oligosaccharide A extracellularly. In this disclosure, "bacteria capable of degrading and utilizing oligosaccharide A extracellularly" means bacteria that degrade oligosaccharide A, the target of degradation, using a degrading enzyme expressed extracellularly, and utilize the resulting degradation products. Degradation products produced by degrading oligosaccharide A extracellularly have the advantage of being able to be efficiently transported to other bacteria or tissues compared to degradation within the bacterial cell.
[0037] Examples of bacteria that can degrade and assimilate oligosaccharide A outside the bacterial cell include, for example, Bifidobacterium (bacteria of the genus Bifidobacterium) that can degrade and assimilate oligosaccharide A outside the bacterial cell, bacteria of the genus Bacteroides that can degrade and assimilate oligosaccharide A outside the bacterial cell, and bacteria of the genus Akkermansia that can degrade and assimilate oligosaccharide A outside the bacterial cell. Preferably, it is Bifidobacterium (bacteria of the genus Bifidobacterium) that can degrade and assimilate oligosaccharide A outside the bacterial cell, and more preferably Bifidobacterium bifidum. Examples of Bifidobacterium bifidum include Bifidobacterium bifidum JCM1254 and the like.
[0038] Examples of the bacteria of the genus Bacteroides that can degrade and assimilate oligosaccharide A outside the bacterial cell include, for example, Bacteroides fragilis (Bacteroides fragilis or B. fragilis), Bacteroides thetaiotaomicron (Bacteroides thetaiotaomicron or B. thetaiotaomicron), and the like. Examples of Bacteroides fragilis include Bacteroides fragilis JCM17586 and the like.
[0039] Examples of the bacteria of the genus Akkermansia that can degrade and assimilate oligosaccharide A outside the bacterial cell include, for example, Akkermansia muciniphila (Akkermansia muciniphila or A. muciniphila) and the like. Examples of Akkermansia muciniphila include Akkermansia muciniphila JCM30893 and the like.
[0040] In another aspect, the bacterium capable of degrading and utilizing oligosaccharide A outside the bacterial cell may be at least one selected from the group consisting of Bifidobacterium bacteria (bacteria of the genus Bifidobacterium) capable of degrading and utilizing oligosaccharide A outside the bacterial cell, Bacteroides bacteria capable of degrading and utilizing oligosaccharide A outside the bacterial cell, and Akkermansia bacteria capable of degrading and utilizing oligosaccharide A outside the bacterial cell, more preferably at least one selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, and Akkermansia muciniphila, and even more preferably at least one selected from the group consisting of Bifidobacterium bifidum JCM1254, Bacteroides fragilis JCM17586, and Akkermansia muciniphila JCM30893.
[0041] The composition according to the present embodiment may be, for example, a composition for promoting butyric acid production by butyrate-producing bacteria. When the composition according to the present embodiment is a composition for promoting butyric acid production by butyrate-producing bacteria, it may be the promotion of butyric acid production by butyrate-producing bacteria using the aforementioned bacterium capable of degrading and utilizing oligosaccharide A and / or the aforementioned fructooligosaccharide (that is, the promotion of butyric acid production by butyrate-producing bacteria using the bacterium capable of degrading and utilizing oligosaccharide A and fructooligosaccharide described later), or it may be the promotion of butyric acid production by butyrate-producing bacteria that is not an application using the aforementioned bacterium capable of degrading and utilizing oligosaccharide A and / or the aforementioned fructooligosaccharide.
[0042] Examples of butyrate-producing bacteria include bacteria of the genus Faecalibacterium, bacteria of the genus Clostridium, or bacteria of the genus Roseburia, and the like, and bacteria of the genus Faecalibacterium are preferred.
[0043] Examples of bacteria of the genus Faecalibacterium include Faecalibacterium prausnitzii (or F. prausnitzii), Faecalibacterium longum (or F. longum), and Faecalibacterium hattorii (or F. hattorii), with Faecalibacterium prausnitzii being preferred.
[0044] Examples of Faecalibacterium prausnizzi include Faecalibacterium prausnizzi JCM31915. Examples of Faecalibacterium longum include Faecalibacterium longum JCM39208. Examples of Faecalibacterium hattori include Faecalibacterium hattori JCM39210.
[0045] Examples of Clostridium bacteria include Clostridium butyricum. An example of Clostridium butyricum is Clostridium butyricum NBRC13949.
[0046] Examples of bacteria belonging to the genus Rosebria include Rosebria intestinalis. An example of Rosebria intestinalis is Rosebria intestinalis JCM17583.
[0047] In this disclosure, "promotion of butyrate production" means a change from a state in which no butyrate is produced to a state in which butyrate is produced, or a change from a state in which butyrate is produced to a state in which the amount of butyrate produced increases.
[0048] In this disclosure, "promotion of butyrate production by butyrate-producing bacteria" refers to the promotion of butyrate production by proliferation of butyrate-producing bacteria and / or by an improvement in the butyrate-producing capacity of butyrate-producing bacteria. Furthermore, the promotion of butyrate production by butyrate-producing bacteria can also be rephrased as the promotion of butyrate production accompanied by an improvement in the butyrate production efficiency per unit cell of the butyrate-producing bacteria and / or the promotion of butyrate production accompanied by an increase in the number of butyrate-producing bacteria. The promotion of butyrate production can be confirmed by the proliferation of butyrate-producing bacteria or an increase in the amount of butyrate using commonly known analytical methods. For example, the number of butyrate-producing bacteria can be measured using an ultraviolet-visible spectrophotometer. 600 Butyrate levels can be measured using methods such as those involving the measurement of genome copy number (qPCR, etc.) or quantitative analysis using fatty acid labeling reagents and HPLC. The growth of butyrate-producing bacteria may be an increase in the absolute number of butyrate-producing bacteria in the gut microbiota, or an increase in the relative abundance of butyrate-producing bacteria compared to other bacteria. Therefore, this disclosure also provides a method for producing butyrate and a method for growing butyrate-producing bacteria. These methods will be described later.
[0049] The absolute number of bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharides, bacteria capable of decomposing and utilizing oligosaccharide A extracellularly, and butyrate-producing bacteria can be confirmed, for example, by measuring turbidity, weight, measuring cellular components such as adenosine triphosphate, using a bacterial counting chamber, counting colonies by culture, or using these measurement kits. Furthermore, the relative abundance ratio of bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharides, bacteria capable of decomposing and utilizing oligosaccharide A extracellularly, and butyrate-producing bacteria in the intestinal microbiota can be confirmed by comparing the results of the above measurements for the bacteria being measured with those of other bacteria. The determination of an increase in these bacteria is based on confirming that the results of the above measurements, when the composition according to this embodiment is applied, show a significant increase or a tendency toward increase compared to before application of the composition according to this embodiment. The degree of increase is not particularly limited as long as there is a significant increase or tendency toward increase compared to when the composition according to this embodiment is not applied. If the composition according to this embodiment is not applied, oligosaccharide A and fructooligosaccharide may be applied individually, or neither oligosaccharide A nor fructooligosaccharide may be applied, but it is preferable that oligosaccharide A and fructooligosaccharide are applied individually.
[0050] The amount of butyric acid can be confirmed, for example, by liquid chromatography, gas chromatography, or a commercially available long-chain / short-chain fatty acid analysis kit. An increase in the amount of butyric acid is indicated, for example, by a significant increase in the amount of butyric acid when the composition according to this embodiment is applied compared to the amount of butyric acid when the composition according to this embodiment is not applied, or by a tendency toward an increase. When the composition according to this embodiment is not applied, for example, oligosaccharide A and fructooligosaccharide may be applied individually, or neither oligosaccharide A nor fructooligosaccharide may be applied, but it is preferable that oligosaccharide A and fructooligosaccharide are applied individually.
[0051] In this disclosure, "promotion of butyrate production in butyrate-producing bacteria using bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharides" may also mean promoting butyrate production in butyrate-producing bacteria by administering or ingesting a combination of "oligosaccharide A and fructooligosaccharides" and bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharides.
[0052] In this disclosure, examples of the degradation products of oligosaccharide A include glucose, galactose, lactose, fucose, and sialic acid, and in the metabolic process of oligosaccharide A in bacteria that can decompose and utilize oligosaccharide A extracellularly, for example, acetic acid is produced. Also in this disclosure, examples of the degradation products of fructooligosaccharides include glucose, fructose, and sucrose, and in the metabolic process of fructooligosaccharides in bacteria that can decompose and utilize fructooligosaccharides, for example, acetic acid is produced. These degradation products or acetic acid lead to, for example, the promotion of butyrate production in butyrate-producing bacteria. Furthermore, these degradation products are utilized by, for example, bacteria that can decompose and utilize oligosaccharide A and / or fructooligosaccharides, and these bacteria also proliferate. The promotion of butyrate production by butyrate-producing bacteria may also be achieved using oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharide, and the mechanism of action is not particularly limited.
[0053] Furthermore, the decomposition products of oligosaccharide A can be obtained by decomposing oligosaccharide A with, for example, sialidase and fucosidase. Similarly, the decomposition products of fructooligosaccharides can be obtained by decomposing fructooligosaccharides with β-fructofuranosidase, inulinase, sucrase, etc. Therefore, butyrate production in butyrate-producing bacteria can also be promoted by bacteria that can excrete the decomposition products of oligosaccharide A and / or fructooligosaccharides produced within the bacterial cell by enzymes that can decompose oligosaccharide A, and by bacteria that can excrete the decomposition products of oligosaccharide A produced within the bacterial cell by enzymes that can decompose oligosaccharide A. In this disclosure, "bacteria capable of excreting the decomposition products of oligosaccharide A and / or fructooligosaccharides produced within the cell by an enzyme capable of decomposing oligosaccharide A and / or fructooligosaccharides" refers to bacteria that can decompose the target oligosaccharide A and / or fructooligosaccharides within the cell using an enzyme expressed within the cell, and excrete the resulting decomposition products outside the cell.
[0054] The administration or ingestion of the above-mentioned oligosaccharide A and the above-mentioned fructooligosaccharide in combination includes, for example, (1) an administration or ingestion of a single composition containing the above-mentioned oligosaccharide A and the above-mentioned fructooligosaccharide, and (2) an administration or ingestion of the above-mentioned oligosaccharide A and the above-mentioned fructooligosaccharide as separate compositions, either simultaneously or separately with a time difference. In the case of (2), the above-mentioned oligosaccharide A may be administered or ingested first, or the above-mentioned fructooligosaccharide may be administered or ingested first. Furthermore, in the case of (2), any of the following may be used: (i) administering or ingesting the oligosaccharide A and the fructooligosaccharide separately at the same time via the same administration or intake route; (ii) administering or ingesting the oligosaccharide A and the fructooligosaccharide separately with a time difference via the same administration or intake route; (iii) administering or ingesting the oligosaccharide A and the fructooligosaccharide separately at the same time via different administration or intake routes (administering from different sites in the same patient); or (iv) administering or ingesting the oligosaccharide A and the fructooligosaccharide separately with a time difference via different administration or intake routes. Note that in the case of (i), both may be mixed immediately before administration or ingestion.
[0055] The administration or ingestion of the above-mentioned oligosaccharide A and / or fructooligosaccharide and the above-mentioned bacteria in combination includes, for example, (1) an embodiment in which the above-mentioned oligosaccharide A and / or fructooligosaccharide and the above-mentioned bacteria are administered or ingested as a single composition, and (2) an embodiment in which the above-mentioned oligosaccharide A and / or fructooligosaccharide and the above-mentioned bacteria are administered or ingested simultaneously or separately with a time difference, as separate compositions. In the case of (2), the above-mentioned oligosaccharide A and / or fructooligosaccharide may be administered or ingested first, or the above-mentioned bacteria may be administered or ingested first. Furthermore, in the case of (2), any of the following may be used: (i) administering or ingesting the above oligosaccharide A and / or the above fructooligosaccharide and the above bacteria separately, simultaneously via the same route of administration or ingestion; (ii) administering or ingesting the above oligosaccharide A and / or the above fructooligosaccharide and the above bacteria separately, with a time difference, via the same route of administration or ingestion; (iii) administering or ingesting the above oligosaccharide A and / or the above fructooligosaccharide and the above bacteria separately, simultaneously via different routes of administration or ingestion (administering from different sites in the same patient); or (iv) administering or ingesting the above oligosaccharide A and / or the above fructooligosaccharide and the above bacteria separately, with a time difference, via different routes of administration. Note that in the case of (i), both may be mixed immediately before administration or ingestion.
[0056] Butyric acid is also called n-butanoic acid, and is "CH 3 (CH 2 ) 2 Butyrate is a compound represented by the structural formula "COOH". In the human small and large intestines, butyrate helps suppress the growth of harmful bacteria and promote the function of beneficial bacteria by lowering the pH. Butyrate is also an energy source for intestinal epithelial cells and suppresses inflammation in the intestines. Therefore, promoting butyrate production can improve diseases such as inflammatory bowel disease and colon cancer, as well as immune function and intestinal barrier function. Accordingly, this disclosure also provides a therapeutic agent or method for treating the above-mentioned diseases that can be treated by promoting butyrate production, and a composition for improving the above-mentioned diseases or a method for promoting health that can obtain the above-mentioned improvement effects. These methods will be described later.
[0057] The compositions according to this embodiment can be administered to or ingested by humans and other mammals, but humans are preferred. Examples of other mammals include mice, rats, guinea pigs, hamsters, rabbits, cats, dogs, sheep, pigs, cattle, horses, goats, and monkeys.
[0058] The human subjects to whom the composition according to this embodiment is administered or ingested are not limited by sex, age, race, country and region, but may be adults, the elderly, children, infants, or newborns.
[0059] The composition according to this embodiment can be administered orally or parenterally, but is preferably administered orally.
[0060] The content of oligosaccharide A or its salt in the composition according to this embodiment is not particularly limited, based on the total amount of the composition, but for example, it is preferably 0.01% by mass or more and less than 100% by mass.
[0061] The content of the fructooligosaccharide or its salt in the composition according to this embodiment is not particularly limited, based on the total amount of the composition, but for example, it is preferably 0.01% by mass or more and less than 100% by mass.
[0062] In the composition according to this embodiment, the ratio of the content (mass%) of oligosaccharide A or its salt relative to the total amount of the composition to the content (mass%) of fructooligosaccharide or its salt relative to the total amount of the composition is, for example, 0.001 or more, 0.002 or more, 0.003 or more, 0.004 or more, 0.005 or more, 0.006 or more, 0.007 or more, 0.008 or more, 0.009 or more, 0.01 or more, 0.02 or more, 0.03 or more, 0.04 or more, 0.05 or less The above may be 0.06 or higher, 0.07 or higher, 0.08 or higher, or 0.09 or higher, and may also be 10 or lower, 9.5 or lower, 9 or lower, 8.5 or lower, 8 or lower, 7.5 or lower, 7 or lower, 6.5 or lower, 6 or lower, 5.5 or lower, 5 or lower, 4.5 or lower, 4 or lower, 3.5 or lower, 3 or lower, 2.5 or lower, 2 or lower, 1.5 or lower, 1 or lower, 0.9 or lower, 0.8 or lower, 0.7 or lower, 0.6 or lower, 0.5 or lower, 0.4 or lower, 0.3 or lower, 0.25 or lower, 0.2 or lower, or 0.1 or lower.
[0063] In the composition according to this embodiment, the ratio of the content of oligosaccharide A or its salt (mass%) based on the total amount of the composition to the content of fructooligosaccharide or its salt (mass%) based on the total amount of the composition is, for example, 0.001 to 10, 0.002 to 9.5, 0.002 to 9, 0.002 to 5, 0.003 to 4, 0.003 to 2.5, 0.004 to 9, 0.004 to 3, 0.004 to 2, 0.005 to 2.5, 0.005 to 1.5, 0.006 to 8.5, 0.006 to 2, 0.006 to 1, 0.007 to 0.7, 0.008 to 8, 0.008 to 1.5, 0.00 8 to 0.5, 0.009 to 0.3, 0.01 to 7.5, 0.01 to 1, 0.01 to 0.25, 0.02 to 7, 0.02 to 0.7 Below, 0.02 to 0.25, 0.03 to 0.25, 0.04 to 6.5, 0.04 to 0.5, 0.04 to 0.25, 0.05 to 0.25 The following ranges may also be 0.06 to 6, 0.06 to 0.45, 0.06 to 0.25, 0.07 to 0.25, 0.08 to 5.5, 0.08 to 0.3, 0.08 to 0.25, 0.09 to 0.25, 0.1 to 5, 0.1 to 4.5, 0.1 to 4, or 0.1 to 0.25.
[0064] When the composition according to this embodiment contains 2'-fucosyl lactose, the ratio of the content of fructooligosaccharides (mass%) relative to the total amount of the composition to the content of 2'-fucosyl lactose (mass%) relative to the total amount of the composition may be 0.001 to 10, 0.002 to 10, 0.003 to 10, 0.004 to 10, 0.005 to 10, 0.006 to 10, 0.007 to 10, 0.008 to 10, 0.009 to 10, or 0.01 to 10. When the ratio of the content of fructooligosaccharides to the content of 2'-fucosyl lactose is as described above, a better butyric acid production efficiency can be obtained than with fructooligosaccharides or 2'-fucosyl lactose alone.
[0065] When the composition according to this embodiment contains 2'-fucosyl lactose, the ratio of the content of fructooligosaccharides (mass%) relative to the total amount of the composition to the content of 2'-fucosyl lactose (mass%) relative to the total amount of the composition is 0.001 to 10, 0.002 to 5, 0.003 to 2.5, 0.004 to 2, 0.005 to 1.5, 0.006 to 1, or 0.007 or higher. The ratio may be 0.7 or less, 0.008 to 0.5, 0.009 to 0.3, 0.01 to 0.3, 0.01 to 0.25, 0.02 to 0.25, 0.03 to 0.25, 0.04 to 0.25, 0.05 to 0.25, 0.06 to 0.25, 0.07 to 0.25, 0.08 to 0.25, 0.09 to 0.25, or 0.1 to 0.25. When the ratio of fructooligosaccharide content to 2'-fucosyllactose content is as described above, using bacteria of the genus Bifidobacterium yields particularly superior butyrate production efficiency compared to fructooligosaccharides or 2'-fucosyllactose alone.
[0066] When the composition according to this embodiment contains 2'-fucosyl lactose, the ratio of the content of fructooligosaccharides (mass%) relative to the total amount of the composition to the content of 2'-fucosyl lactose (mass%) relative to the total amount of the composition is 0.001 to 10, 0.002 to 9, 0.003 to 8.5, 0.004 to 7, 0.005 to 6.5, or 0.006 or higher. The ratio may be 6 or less, 0.007 to 5.5, 0.008 to 5, 0.009 to 4.5, 0.01 to 4, 0.02 to 3.5, 0.03 to 3, 0.04 to 2.5, 0.05 to 2, 0.06 to 1.5, 0.07 to 1.5, 0.08 to 1.5, 0.1 to 1.5, 0.1 to 1.5, or 0.1 to 0.5. When the ratio of fructooligosaccharide content to 2'-fucosyllactose content is as described above, using bacteria of the genus Bacteroides yields particularly superior butyrate production efficiency compared to fructooligosaccharides or 2'-fucosyllactose alone.
[0067] If the composition according to this embodiment contains 2'-fucosyl lactose, the ratio of the content of fructooligosaccharides (mass%) relative to the total amount of the composition to the content of 2'-fucosyl lactose (mass%) relative to the total amount of the composition may be 0.001 to 10, 0.002 to 10, 0.003 to 10, 0.004 to 10, 0.005 to 10, 0.006 to 10, 0.007 to 10, 0.008 to 10, 0.009 to 10, 0.01 to 10, 0.02 to 9, 0.03 to 9, 0.04 to 9, 0.05 to 9, 0.06 to 9, 0.07 to 9, 0.08 to 9, 0.1 to 9, 1 to 2, or 1 to 1.5. When the ratio of fructooligosaccharide content to 2'-fucosyllactose content is as described above, using bacteria of the genus Akkermansia yields particularly superior butyrate production efficiency compared to fructooligosaccharides or 2'-fucosyllactose alone.
[0068] When the composition according to this embodiment contains 3'-sialyl lactose, the ratio of the content of fructooligosaccharides (mass%) relative to the total amount of the composition to the content of 3'-sialyl lactose (mass%) relative to the total amount of the composition may be 0.001 to 10, 0.002 to 9, 0.003 to 4, 0.004 to 3, 0.005 to 2.5, 0.006 to 2, 0.008 to 1.5, 0.01 to 1, 0.02 to 0.7, 0.04 to 0.5, 0.06 to 0.45, 0.08 to 0.3, or 0.1 to 0.25. When the ratio of the content of fructooligosaccharides to the content of 3'-sialyl lactose is as described above, a better butyric acid production efficiency can be obtained than with fructooligosaccharides or 3'-sialyl lactose alone.
[0069] When the composition according to this embodiment contains 6'-sialyl lactose, the ratio of the content of fructooligosaccharides (mass%) relative to the total amount of the composition to the content of 6'-sialyl lactose (mass%) relative to the total amount of the composition may be 0.001 to 10, 0.002 to 9.5, 0.004 to 9, 0.006 to 8.5, 0.008 to 8, 0.01 to 7.5, 0.02 to 7, 0.04 to 6.5, 0.06 to 6, 0.08 to 5.5, 0.1 to 5, 0.1 to 4.5, or 0.1 to 4.0. When the ratio of the content of fructooligosaccharides to the content of 6'-sialyl lactose is as described above, a better butyric acid production efficiency can be obtained than with fructooligosaccharides or 6'-sialyl lactose alone.
[0070] The schedule for administering or ingesting the composition according to this embodiment may include once to three times a day for two days or more, or for one week or more, and this is repeated.
[0071] The dosage or intake of the composition according to this embodiment is not particularly limited, but for example, for a subject weighing 60 kg, the daily dosage or intake of oligosaccharide A or its salt and fructooligosaccharide or its salt may be 50 mg to 30 g or 100 mg to 10 g.
[0072] The composition according to this embodiment may be for food and beverage use, or for pharmaceutical use, and may be a food and beverage composition such as food and beverages, or a pharmaceutical composition such as a pharmaceutical or quasi-drug. Food and beverage compositions such as food and beverages, and pharmaceutical compositions such as pharmaceuticals or quasi-drugs, can each be manufactured in accordance with conventional methods. The content of oligosaccharide A or its salt and the content of fructooligosaccharide or its salt in the food and beverage, pharmaceutical or quasi-drug are not particularly limited and can be freely set according to the purpose, and may be as described above.
[0073] When the composition according to this embodiment is a food or beverage composition or a pharmaceutical composition, the food or beverage composition or pharmaceutical composition may contain, in addition to the above-mentioned oligosaccharide A or its salt and fructooligosaccharide or its salt, components that can be commonly used in food or beverage compositions or pharmaceutical compositions. The food or beverage composition or pharmaceutical composition according to this embodiment may contain bases, carriers, additives, etc., that are commonly used in food or beverage compositions or pharmaceutical compositions. Examples of additives include excipients, oils, powders, buffers, solubilizers, antioxidants, surfactants, thickeners, preservatives, pH adjusters, chelating agents, stabilizers, irritation reducers, preservatives, pigments, colorants, fragrances, gloss enhancers, gelling agents, alcohols, water-soluble polymers, film-forming agents, resins, etc. The bases, carriers, and the various additives described above can be used individually or in combination as needed.
[0074] When the composition according to this embodiment is used as a food or beverage composition, there are no restrictions on the category or type of food or beverage, and examples include general food and beverages, as well as foods for the sick, health foods, functional foods, foods for specified health uses, nutritional supplements, and other supplements.
[0075] When the composition according to this embodiment is used as a food or beverage composition, examples of food or beverage compositions include various beverages, various foods, processed foods, liquid foods (soups, etc.), seasonings, nutritional drinks, and confectionery. In this specification, "processed food" means a product made by processing and / or cooking natural ingredients (e.g., animals and plants, etc.). Examples of processed foods include processed meat products, processed vegetable products, processed fruit products, frozen foods, retort foods, canned foods, bottled foods, and instant foods. Food and beverages may also be provided in a form sealed in a bag or container, and any bag or container commonly used for food can be used.
[0076] In this disclosure, there are no particular restrictions on the form of the food and beverage composition. For example, it can take any food form that is normally available for distribution, such as solid (e.g., powder and granules), liquid, liquid food, jelly, tablet, granule, capsule, paste, or suspension. The food and beverage composition can be manufactured using commonly known methods, and carbohydrates, proteins, lipids, dietary fiber, vitamins, essential trace metals (e.g., manganese sulfate, zinc sulfate, magnesium chloride, and potassium carbonate), flavorings, etc., may be added.
[0077] Furthermore, the food and beverage composition may be, for example, the food or beverage itself, or it may be a material used in the manufacture of food and beverages. Examples of such materials include seasonings, food additives, or other food and beverage ingredients. Specific examples of food and beverage compositions include wheat flour products, instant foods, processed agricultural products, processed marine products, processed livestock products, dairy products (fermented milk, cheese, infant formula, etc.), oils and fats, basic seasonings, compound seasonings, frozen foods, confectionery, beverages, or other commercially available food and beverages. In addition, specific examples of food and beverage compositions include health foods, functional foods, enteral nutrition foods, foods for special dietary uses, nutritional function foods, health functional foods (foods for specified health uses, nutritional function foods, foods with functional claims, etc.), or nutritional supplements. The food and beverage composition may also be a supplement, such as a tablet supplement.
[0078] Food and beverage compositions can be manufactured, for example, by combining an active ingredient (for example, in the composition according to this embodiment, oligosaccharide A or a salt thereof, and fructooligosaccharide or a salt thereof) with additional ingredients. The operation of combining an active ingredient with additional ingredients is also called "addition of the active ingredient." The method for manufacturing the food and beverage composition according to this embodiment is not particularly limited. Except for the addition of the active ingredient, the food and beverage composition according to this embodiment can be manufactured, for example, using the same raw materials as ordinary food and beverages and using the same methods as ordinary food and beverages. The same applies when the food and beverage composition according to this embodiment is manufactured as a material used in the manufacture of food and beverages. The addition of the active ingredient may be carried out at any stage in the manufacturing process of the food and beverage composition. The addition of the active ingredient may be carried out, for example, during or after the manufacture of the food and beverage composition. That is, for example, the food and beverage composition according to this embodiment may be manufactured by adding the active ingredient to a pre-prepared food or beverage.
[0079] Furthermore, other food and beverage compositions can be manufactured using the food and beverage compositions according to this embodiment. That is, for example, if the food and beverage compositions according to this embodiment are provided as materials used in the manufacture of food and beverages (e.g., seasonings, food additives, or other food and beverage ingredients), other food and beverage compositions may be manufactured by adding the food and beverage compositions according to this embodiment. Such other food and beverage compositions are also examples of food and beverage compositions according to this embodiment. The description of the addition of active ingredients in the manufacture of food and beverage compositions can be applied mutatis mutandis to the addition of the food and beverage compositions according to this embodiment in the manufacture of food and beverage compositions.
[0080] As described above, the food and beverage compositions according to this embodiment may be provided and sold as food and beverages with a specified use indicated (including health use, functional use, enteral nutrition use, special use, nutritional function use, health function use, and nutritional supplement use). The food and beverage compositions according to this embodiment may be provided and sold as food and beverages with an indicated target.
[0081] "Display" includes all actions taken to inform consumers of the aforementioned use, and any expression that can evoke or infer the aforementioned use constitutes a "display," regardless of the purpose, content, object, or medium of the display. In particular, the display may be carried out using an expression that allows consumers to directly recognize the aforementioned use.
[0082] Specifically, examples of indications include transferring, delivering, displaying for transfer or delivery, or importing a product relating to the food and beverage composition according to this embodiment, or a product whose packaging has the aforementioned use described on it; displaying or distributing an advertisement, price list, or transaction document relating to the product that includes the aforementioned use; or providing information containing such information by electromagnetic means (such as the Internet). Examples of indications include indications on packaging, containers, catalogs, brochures, promotional materials at sales sites (POP, etc.), or other documents.
[0083] Examples of labeling include labels for health foods, functional foods, enteral nutrition foods, foods for special dietary uses, health functional foods (foods for specified health uses, nutrient function foods, foods with functional claims, etc.), and nutritional supplements. Preferably, the labeling is approved by the government or other authorities (for example, labels approved under various systems established by the government and made in accordance with such approval). Examples of labels approved by the government or other authorities include labels approved by the Consumer Affairs Agency of Japan. In the case of food and beverage compositions, examples of labels approved by the Consumer Affairs Agency of Japan include labels approved under the health functional food system (foods for specified health uses, nutrient function foods, foods with functional claims, etc.) and similar systems. Specifically, examples of labels approved by the Consumer Affairs Agency of Japan include labels as foods for specified health uses, labels as conditionally specified health uses, labels indicating an effect on the structure or function of the body, labels indicating a reduction in disease risk, and labels indicating scientifically based functionality. For example, more specifically, as a form of labeling approved by the Consumer Affairs Agency of Japan, examples include labeling as a Food for Specified Health Uses (especially labeling for health purposes) as defined in the Cabinet Office Ordinance concerning the Permission for Special Use Labeling under the Health Promotion Act (Cabinet Office Ordinance No. 57 of August 31, 2009), and similar labeling.
[0084] The composition (pharmaceutical composition) according to this embodiment can be made into a formulation that is easy to administer or ingest. Such dosage forms may include any of the following: oral preparations such as tablets, powders, granules, pills, suspensions, emulsions, infusions / decoctions, capsules, syrups, liquids, elixirs, extracts, tinctures and fluid extracts, and parenteral preparations such as injections, drips, creams and suppositories, but oral preparations are preferred.
[0085] The method of formulation is not particularly limited. Formulation can be carried out, for example, by known methods depending on the dosage form. Physiologically acceptable additives can be used in formulation. Examples of additives include various organic and inorganic components. Specifically, examples of additives include excipients, binders, disintegrants, lubricants, stabilizers, flavoring and odor-correcting agents, pH adjusters, colorants, diluents, surfactants, and solvents. These additives can be appropriately selected, for example, depending on various conditions such as the dosage form.
[0086] Excipients include sugar derivatives such as lactose, sucrose, glucose, mannitol, and sorbitol; starch derivatives such as corn starch, potato starch, α-starch, dextrin, and carboxymethyl starch; cellulose derivatives such as crystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, and carboxymethylcellulose calcium; gum arabic; dextran; pullulan; silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminometasilicate; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium carbonate; and sulfate derivatives such as calcium sulfate.
[0087] In addition to the above-mentioned excipients, other examples of binders include gelatin, polyvinylpyrrolidone, and macrogol.
[0088] In addition to the above-mentioned excipients, disintegrants include chemically modified starch or cellulose derivatives such as croscarmellose sodium, carboxymethyl starch sodium, and cross-linked polyvinylpyrrolidone.
[0089] Examples of lubricants include talc; stearic acid; metal stearate salts such as calcium stearate and magnesium stearate; colloidal silica; waxes such as beecam and gayl wax; boric acid; glycol; carboxylic acids such as fumaric acid and adipic acid; sodium carboxylate salts such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acid such as anhydrous silicic acid and silicic acid hydrate; and starch derivatives.
[0090] Examples of stabilizers include para-hydroxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol, and phenylethyl alcohol; benzalkonium chloride; acetic anhydride; and sorbic acid.
[0091] Flavoring and odor-modifying agents include sweeteners, acidulants, and flavorings.
[0092] This disclosure provides a composition containing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, which is administered or ingested in combination with fructooligosaccharides or salts thereof.
[0093] This disclosure provides a composition containing a fructooligosaccharide or a salt thereof, which is administered or ingested in combination with at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof.
[0094] This disclosure provides a composition for use in applications employing the bacteria, comprising, as an active ingredient, at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, and a fructooligosaccharide or a salt thereof, and a bacterium capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide.
[0095] If the composition used for applications employing the bacteria according to this embodiment contains bacteria capable of decomposing and utilizing the oligosaccharide A and / or fructooligosaccharide, the amount of bacteria capable of decomposing and utilizing the oligosaccharide A and / or fructooligosaccharide in the composition is not particularly limited, but the dry weight of the bacteria relative to the total mass of the composition may be, for example, 0.01% by mass or more and less than 100% by mass, 0.01% by mass or more and 95% by mass or less, 0.01% by mass or more and 90% by mass or less, 0.01% by mass or more and 85% by mass or less, or 0.01% by mass or more and 80% by mass or less.
[0096] This disclosure provides a composition for use in applications employing the bacterium, comprising, as an active ingredient, a bacterium capable of decomposing and utilizing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides.
[0097] This disclosure provides a bacterium capable of decomposing and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, and a composition for use in applications employing the bacterium, which contains the oligosaccharide A or a salt thereof as an active ingredient and is administered or ingested in combination with the fructooligosaccharide or a salt thereof.
[0098] This disclosure provides a bacterium capable of decomposing and assimilating at least one oligosaccharide A and / or fructooligosaccharide selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and a composition for use in applications employing the bacterium, which contains the fructooligosaccharide or a salt thereof as an active ingredient and is administered or ingested in combination with the oligosaccharide A or a salt thereof.
[0099] This disclosure provides a composition for use in applications employing the bacteria, which contains, as an active ingredient, at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, and a salt thereof, and which is administered or ingested in combination with the bacteria capable of decomposing and utilizing the oligosaccharide A and / or fructooligosaccharide.
[0100] This disclosure provides a composition for use in applications employing bacteria, comprising, as an active ingredient, a bacterium capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide, which is administered or ingested in combination with at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and a bacterium capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide.
[0101] This disclosure provides the use of oligosaccharide A or a salt thereof, fructooligosaccharide or a salt thereof, and the bacteria for producing a composition for use in applications that utilize bacteria capable of degrading and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides.
[0102] This disclosure provides the use of oligosaccharide A or a salt thereof, and fructooligosaccharide or a salt thereof, for producing a composition for use in applications employing a bacterium capable of degrading and utilizing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides.
[0103] This disclosure provides the use of bacteria for producing a composition for use in applications that utilize bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide, using at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and a fructooligosaccharide or a salt thereof.
[0104] This disclosure provides a bacterium capable of degrading and utilizing at least one oligosaccharide A and / or fructooligosaccharide selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and the use of oligosaccharide A or a salt thereof for use in applications employing the bacterium, which is administered or ingested in combination with the fructooligosaccharide or a salt thereof.
[0105] This disclosure provides a bacterium capable of degrading and utilizing at least one oligosaccharide A and / or fructooligosaccharide selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and the use of the fructooligosaccharide or a salt thereof for use in applications employing the bacterium, which is administered or ingested in combination with the oligosaccharide A or a salt thereof.
[0106] This disclosure provides the use of oligosaccharide A or a salt thereof, and fructooligosaccharide or a salt thereof, for producing a composition for use in applications using the bacteria, which is administered or ingested in combination with bacteria capable of degrading and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides.
[0107] This disclosure provides the use of bacteria for producing a composition for use in applications that utilize bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide, which is administered or ingested in combination with at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and a fructooligosaccharide or a salt thereof.
[0108] This disclosure provides oligosaccharide A or a salt thereof and fructooligosaccharide or a salt thereof for use in applications using bacteria that can decompose and utilize at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides.
[0109] This disclosure provides a bacterium capable of degrading and utilizing the oligosaccharide A and / or fructooligosaccharide for use in applications that utilize a bacterium capable of degrading and utilizing the oligosaccharide A and / or fructooligosaccharide, using at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and a fructooligosaccharide or a salt thereof.
[0110] This disclosure provides an oligosaccharide A or a salt thereof for use in a therapeutic method using a bacterium capable of degrading and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, wherein the oligosaccharide A or a salt thereof is administered or ingested in combination with the bacterium and the fructooligosaccharide or salt thereof.
[0111] This disclosure provides a fructooligosaccharide or a salt thereof for use in a therapeutic method using bacteria capable of degrading and assimilating at least one oligosaccharide A and / or fructooligosaccharide selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, wherein the fructooligosaccharide or a salt thereof is administered or ingested in combination with the bacteria and the oligosaccharide A or salt thereof.
[0112] This disclosure provides a composition for use in a therapeutic method using bacteria capable of degrading and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, the composition containing oligosaccharide A or a salt thereof and fructooligosaccharide or a salt thereof, which is administered or ingested in combination with the bacteria.
[0113] This disclosure provides a bacterium capable of degrading and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, for use in a therapeutic method using a bacterium capable of degrading and assimilating the oligosaccharide A and / or fructooligosaccharide, which is administered or ingested in combination with the oligosaccharide A or a salt thereof and the fructooligosaccharide or a salt thereof.
[0114] This disclosure provides a use of oligosaccharide A or a salt thereof in a non-therapeutic method using bacteria capable of degrading and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, wherein the bacteria capable of degrading and assimilating oligosaccharide A and / or fructooligosaccharides are administered or ingested in combination with the fructooligosaccharide or a salt thereof.
[0115] This disclosure provides a use of a fructooligosaccharide or a salt thereof in a non-therapeutic method using bacteria capable of degrading and assimilating at least one oligosaccharide A and / or fructooligosaccharide selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, wherein the fructooligosaccharide or a salt thereof is administered or ingested in combination with the bacteria and the oligosaccharide A or a salt thereof.
[0116] This disclosure provides a use of a composition containing oligosaccharide A or a salt thereof and fructooligosaccharide or a salt thereof in a non-therapeutic method using bacteria capable of degrading and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, wherein the composition is administered or ingested in combination with the bacteria.
[0117] This disclosure provides a use in a non-therapeutic method using bacteria capable of degrading and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, wherein the bacteria are administered or ingested in combination with the oligosaccharide A or a salt thereof, and the fructooligosaccharide or a salt thereof.
[0118] This disclosure provides a method for treating a disease that can be treated with the bacteria, or a method for promoting health that can obtain an improvement effect, comprising the step of administering or ingesting at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof, a fructooligosaccharide or a salt thereof, and bacteria capable of decomposing and assimilating the oligosaccharide A and / or fructooligosaccharide.
[0119] This disclosure provides a method for treating a disease or a method for promoting health that can be obtained by using bacteria capable of decomposing and assimilating oligosaccharide A and / or fructooligosaccharide, comprising the step of administering at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and a fructooligosaccharide or a salt thereof.
[0120] This disclosure provides a composition for promoting butyrate production in butyrate-producing bacteria, comprising at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, and a fructooligosaccharide or a salt thereof as active ingredients.
[0121] This disclosure provides a composition for promoting butyrate production in butyrate-producing bacteria, which contains as an active ingredient at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, to be administered or ingested in combination with fructooligosaccharides or a salt thereof.
[0122] This disclosure provides a composition for promoting butyrate production in butyrate-producing bacteria, which contains a fructooligosaccharide or a salt thereof as an active ingredient, and is administered or ingested in combination with at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof.
[0123] This disclosure provides the use of at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, and a fructooligosaccharide or a salt thereof, for producing a composition for promoting butyrate production in butyrate-producing bacteria.
[0124] This disclosure provides the use of at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, for producing a composition for promoting butyrate production in butyrate-producing bacteria, which is administered or ingested in combination with fructooligosaccharides or salts thereof.
[0125] This disclosure provides the use of fructooligosaccharides or salts thereof for producing a composition for promoting butyrate production in butyrate-producing bacteria, which is administered or ingested in combination with at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof.
[0126] This disclosure provides at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, and a fructooligosaccharide or a salt thereof, for use in promoting butyrate production in butyrate-producing bacteria.
[0127] This disclosure provides at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, for use in a therapeutic method to promote butyrate production in butyrate-producing bacteria, wherein the oligosaccharide A or a salt thereof is administered or ingested in combination with a fructooligosaccharide or a salt thereof.
[0128] This disclosure provides a fructooligosaccharide or a salt thereof for use in a therapeutic method to promote butyrate production in butyrate-producing bacteria, which is administered or ingested in combination with at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof.
[0129] This disclosure provides a use in a non-therapeutic method for promoting butyrate production in butyrate-producing bacteria, comprising the use of at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, which is administered or ingested in combination with the fructooligosaccharide or salt thereof.
[0130] This disclosure provides a use of fructooligosaccharides or salts thereof in a non-therapeutic method for promoting butyrate production in butyrate-producing bacteria, wherein the fructooligosaccharides or salts thereof are administered or ingested in combination with at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof.
[0131] This disclosure provides a method for treating a disease that can be treated by promoting butyrate production in butyrate-producing bacteria, or a method for promoting health that can provide an improvement effect, comprising the step of administering or ingesting at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, and a fructooligosaccharide or a salt thereof.
[0132] In the treatment method or health promotion method according to this embodiment, when administering or ingesting bacteria capable of decomposing and utilizing oligosaccharide A outside the cell, the amount of the butyrate production promoting composition according to this embodiment administered or ingested is not particularly limited, but for example, for a target with a body weight of 60 kg, 1 × 10 per day 7 ~1 x 10 13cells, 1×10 8 to 1×10 12 cells, or 1×10 9 to 1×10 11 cells. The administration subject and the like are as described above.
[0133] The present disclosure provides a method for producing butyric acid, comprising the step of allowing at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and fructooligosaccharides or a salt thereof to act on butyric acid-producing bacteria.
[0134] The present disclosure provides a method for proliferating butyric acid-producing bacteria, comprising the step of allowing at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and fructooligosaccharides or a salt thereof to act on butyric acid-producing bacteria.
[0135] In the present disclosure, "act on" may mean bringing into contact, allowing to coexist, or co-culturing.
[0136] The present disclosure provides a composition for promoting butyric acid production by butyric acid-producing bacteria, comprising, as active ingredients: at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides; fructooligosaccharides or a salt thereof; and bacteria capable of degrading and assimilating the oligosaccharide A and / or the fructooligosaccharides.
[0137] The present disclosure provides a composition for promoting butyric acid production by butyric acid-producing bacteria using at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and fructooligosaccharides or a salt thereof, the composition comprising, as an active ingredient, bacteria capable of degrading and assimilating at least one selected from the group consisting of the oligosaccharide A and the fructooligosaccharides.
[0138] If the butyric acid production promoting composition according to this embodiment contains bacteria capable of decomposing and utilizing the above-mentioned oligosaccharide A and / or fructooligosaccharide, the amount of bacteria capable of decomposing and utilizing the above-mentioned oligosaccharide A and / or fructooligosaccharide in the composition is not particularly limited, but the dry weight of the bacteria relative to the total mass of the composition may be, for example, 0.01% by mass or more and less than 100% by mass, 0.01% by mass or more and 95% by mass or less, 0.01% by mass or more and 90% by mass or less, 0.01% by mass or more and 85% by mass or less, or 0.01% by mass or more and 80% by mass or less.
[0139] This disclosure provides a bacterium capable of decomposing and utilizing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and / or the fructooligosaccharide, and a composition for promoting butyrate production in butyrate-producing bacteria, which contains the oligosaccharide A or a salt thereof as an active ingredient and is administered or ingested in combination with the fructooligosaccharide or a salt thereof.
[0140] This disclosure provides a bacterium capable of decomposing and utilizing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and / or the fructooligosaccharide, and a composition for promoting butyrate production by butyrate-producing bacteria, which contains the fructooligosaccharide or its salt as an active ingredient and is administered or ingested in combination with the oligosaccharide A or its salt.
[0141] This disclosure provides a composition for promoting butyrate production in butyrate-producing bacteria, which contains, as an active ingredient, at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and / or a bacterium capable of decomposing and utilizing the fructooligosaccharide, and the oligosaccharide A or a salt thereof.
[0142] This disclosure provides a composition for promoting butyrate production by butyrate-producing bacteria, which contains, as an active ingredient, a bacterium capable of decomposing and utilizing the oligosaccharide A and / or fructooligosaccharide, which is administered or ingested in combination with at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and a fructooligosaccharide or a salt thereof.
[0143] This disclosure provides for the use of at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, a fructooligosaccharide or a salt thereof, and bacteria capable of decomposing and assimilating said oligosaccharide A and / or said fructooligosaccharide, for producing a composition for promoting butyrate production by butyrate-producing bacteria.
[0144] This disclosure provides the use of oligosaccharide A or a salt thereof, and fructooligosaccharide or a salt thereof, for producing a composition for promoting butyrate production in butyrate-producing bacteria using bacteria that can decompose and utilize at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and / or fructooligosaccharides.
[0145] This disclosure provides the use of bacteria capable of decomposing and assimilating oligosaccharide A and / or fructooligosaccharide for producing a composition for promoting butyrate production in butyrate-producing bacteria, using at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and fructooligosaccharide or a salt thereof.
[0146] This disclosure provides a bacterium capable of degrading and utilizing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, and the use of the oligosaccharide A or a salt thereof for producing a composition for promoting butyrate production in butyrate-producing bacteria, which is administered or ingested in combination with the fructooligosaccharide or a salt thereof.
[0147] This disclosure provides a bacterium capable of decomposing and utilizing at least one oligosaccharide A and / or fructooligosaccharide selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and the use of the fructooligosaccharide or a salt thereof for producing a composition for promoting butyrate production in butyrate-producing bacteria, which is administered or ingested in combination with the oligosaccharide A or a salt thereof.
[0148] This disclosure provides the use of oligosaccharide A or a salt thereof, and fructooligosaccharide or a salt thereof, for producing a composition for promoting butyrate production in butyrate-producing bacteria, which is administered or ingested in combination with bacteria capable of degrading and utilizing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides.
[0149] This disclosure provides the use of bacteria capable of degrading and utilizing oligosaccharide A and / or fructooligosaccharide for producing a composition for promoting butyrate production by butyrate-producing bacteria, which is administered or ingested in combination with at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof and a fructooligosaccharide or a salt thereof.
[0150] This disclosure provides oligosaccharide A or a salt thereof, and fructooligosaccharide or a salt thereof, for use in promoting butyrate production in butyrate-producing bacteria using bacteria that can decompose and utilize at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides.
[0151] This disclosure provides at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and bacteria capable of degrading and utilizing the oligosaccharide A and / or the fructooligosaccharide for use in promoting butyrate production in butyrate-producing bacteria using fructooligosaccharides or salts thereof.
[0152] This disclosure provides at least one oligosaccharide A or a salt thereof, selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, for use in a therapeutic method to promote butyrate production in butyrate-producing bacteria, wherein the oligosaccharide A or a salt thereof is administered or ingested in combination with bacteria capable of decomposing and utilizing the oligosaccharide A and / or fructooligosaccharides, and the fructooligosaccharide or salt thereof.
[0153] This disclosure provides a fructooligosaccharide or a salt thereof for use in a therapeutic method to promote butyrate production in butyrate-producing bacteria, wherein the fructooligosaccharide or a salt thereof is administered or ingested in combination with a bacterium capable of degrading and utilizing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or the fructooligosaccharide, and the oligosaccharide A or a salt thereof.
[0154] This disclosure provides a composition for use in a therapeutic method to promote butyrate production by butyrate-producing bacteria, comprising at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, and a fructooligosaccharide or a salt thereof, which is administered or ingested in combination with bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide.
[0155] This disclosure provides a bacterium capable of degrading and assimilating at least one oligosaccharide A and / or fructooligosaccharide selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, for use in a therapeutic method to promote butyrate production in butyrate-producing bacteria, which is administered or ingested in combination with the oligosaccharide A or a salt thereof and the fructooligosaccharide or a salt thereof.
[0156] This disclosure provides a use in a non-therapeutic method for promoting butyrate production in butyrate-producing bacteria, comprising the use of at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, wherein the oligosaccharide A and / or fructooligosaccharides are administered or ingested in combination with bacteria capable of decomposing and assimilating the oligosaccharide A and / or fructooligosaccharides, and the fructooligosaccharides or salts thereof.
[0157] This disclosure provides a use of fructooligosaccharides or salts thereof in a non-therapeutic method for promoting butyrate production in butyrate-producing bacteria, wherein the fructooligosaccharides or salts thereof are administered or ingested in combination with bacteria capable of degrading and utilizing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or the fructooligosaccharides.
[0158] This disclosure provides a use in a non-therapeutic method for promoting butyrate production in butyrate-producing bacteria, the use of a composition containing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, and a fructooligosaccharide or a salt thereof, wherein the composition is administered or ingested in combination with bacteria capable of degrading and assimilating the oligosaccharide A and / or the fructooligosaccharide.
[0159] This disclosure provides a use in a non-therapeutic method for promoting butyrate production by butyrate-producing bacteria, the use of bacteria capable of degrading and assimilating at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides and / or fructooligosaccharides, wherein the oligosaccharide A or a salt thereof and the fructooligosaccharide or a salt thereof are administered or ingested in combination.
[0160] This disclosure provides a method for treating a disease that can be treated by promoting butyrate production by butyrate-producing bacteria, or a method for promoting health that can obtain an improvement effect, comprising the steps of administering or ingesting at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof, a fructooligosaccharide or a salt thereof, and bacteria capable of decomposing and utilizing the oligosaccharide A and / or fructooligosaccharide.
[0161] This disclosure provides a method for treating a disease that can be treated by promoting butyrate production in butyrate-producing bacteria using bacteria capable of decomposing and utilizing oligosaccharide A and / or fructooligosaccharide, comprising the step of administering at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and a fructooligosaccharide or a salt thereof.
[0162] This disclosure provides a method for producing butyric acid, comprising the step of acting on bacteria and butyrate-producing bacteria that can decompose and utilize the oligosaccharide A and / or fructooligosaccharides, at least one oligosaccharide A or a salt thereof selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, and a fructooligosaccharide or a salt thereof.
[0163] This disclosure provides a method for producing butyrate, comprising the step of acting on a butyrate-producing bacterium with at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof, a fructooligosaccharide or a salt thereof, and bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide.
[0164] This disclosure provides a method for growing butyrate-producing bacteria, comprising the step of acting on butyrate-producing bacteria with at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides or a salt thereof, a fructooligosaccharide or a salt thereof, and bacteria capable of decomposing and utilizing the oligosaccharide A and / or the fructooligosaccharide.
[0165] In the above-described composition, use, oligosaccharide A or its salt, fructooligosaccharide or its salt, bacteria, and method, the ratio of the dose or intake of oligosaccharide A or its salt to the dose or intake of fructooligosaccharide or its salt may be the same as the ratio of the content of oligosaccharide A or its salt (mass%) relative to the total amount of the composition to the content of fructooligosaccharide or its salt (mass%) relative to the total amount of the composition.
[0166] With regard to the specific embodiments of the composition, use, oligosaccharide A or its salt, fructooligosaccharide or its salt, bacteria, and method according to the above embodiment, the specific embodiments described above can be applied without particular limitation.
[0167] The present invention will be described more specifically below based on examples. However, the present invention is not limited to the following examples.
[0168] <Test Example 1: Evaluation of the butyrate production-promoting effect of compositions combining 2'-FL, 3'-SL, or 6'-SL with fructooligosaccharides in co-culture of Faecalibacterium prausnitzii and Bifidobacterium bifidum> The butyrate production-promoting effect of combination formulations of 2'-FL, 3'-SL, or 6'-SL with fructooligosaccharides on Faecalibacterium prausnitzii was evaluated by culturing Faecalibacterium prausnitzii and Bifidobacterium bifidum in a test medium containing 2'-FL, 3'-SL, or 6'-SL and fructooligosaccharides (a mixture of 1-kestose, nistose, and 1-fructofuranosyl-D-nistose) (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., catalog number 062-02381) on Faecalibacterium prausnitzii using the procedure described below.
[0169] The culture medium used was YCFAG medium from which the sugar source and VFA mix had been removed (hereinafter referred to as YCFA-medium). To prepare YCFAG medium, the reagents listed in Table 1 were mixed, and the pH was adjusted to 7.45 ± 0.05 with a 1 mol / L sodium hydroxide aqueous solution (Fujifilm Wako Pure Chemical Industries, Ltd.). After autoclaving, 1 mL / L Vitamin Solution II (Table 7) and 10 mL / L Hemin Solution (Table 8) were added. The sugar sources used in the study were glucose, fructooligosaccharides, 2'-FL, 3'-SL, 6'-SL, and compositions combining fructooligosaccharides and 2'-FL (Table 9), compositions combining fructooligosaccharides and 3'-SL (Table 10), and compositions combining fructooligosaccharides and 6'-SL (Table 11). Glucose and fructooligosaccharides were purchased from Fujifilm Wako Pure Chemical Industries, Ltd. 2'-FL, 3'-SL, and 6'-SL were obtained from Kyowa Hakko Bio. Each sugar source was added to YCFA medium to a final concentration of 5 g / L to prepare the test medium.
[0170]
[0171]
[0172]
[0173]
[0174]
[0175]
[0176]
[0177]
[0178]
[0179]
[0180]
[0181] We purchased Faecalibacterium prausnizzi (JCM31915) and Bifidobacterium bifidum (JCM1254) from the RIKEN BioResource Research Center. Single colonies of each strain were inoculated into YCFAG medium and incubated overnight at 37°C. The overnight culture solution was centrifuged at 6,000 x g for 5 minutes, and the supernatant was removed. 600 The suspensions were resuspended in YCFA medium to a ratio of 1.0. The suspensions of Faecalibacterium prausnizzi and Bifidobacterium bifidum were inoculated into each test medium at a 1 / 100 ratio and incubated at 37°C for 24 hours. All incubation was performed under anaerobic conditions. The culture solution was centrifuged at 15,000 rpm for 5 minutes at 4°C, and the culture supernatant was collected. The amount of short-chain fatty acids in the culture supernatant was measured using the YMC-Pack FA short-chain fatty acid analysis reagent (YMC Corporation).
[0182] Tables 12-14 and Figures 1-3 show the butyric acid concentrations in the culture supernatant under conditions A-1 to A-11, B-1 to B-11, and C-1 to C-9, respectively. In Tables 12-14 and Figures 1-3, "*" and "**" indicate a significant difference compared to the group to which fructooligosaccharides were added alone (*: p < 0.05, **: p < 0.01, Tukey test). In Tables 12-14 and Figures 1-3, "#" and "##" indicate a significant difference compared to the group to which 2'-FL, 3'-SL, or 6'-SL were added alone (#: p < 0.05, ##: p < 0.01, Tukey test).
[0183]
[0184]
[0185]
[0186] It was confirmed that adding 2'-FL, 3'-SL, or 6'-SL to fructooligosaccharides in predetermined ratios to Faecalibacterium prausnitzii and Bifidobacterium bifidum resulted in a significant increase in butyrate production (p < 0.01) compared to groups where each oligosaccharide was added alone. More specifically, a synergistic increase in butyrate production was observed in the following mixing ratios: 90:10 for fructooligosaccharide and 2'-FL, 90:10 and 80:20 for fructooligosaccharide and 3'-SL, and 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70 and 20:80 for fructooligosaccharide and 6'-SL.
[0187] Bifidobacterium bifidum is known to grow by utilizing oligosaccharides such as 2'-FL, 3'-SL, and 6'-SL, and to produce acetic acid. Similarly, Faecalibacterium prausnizzi is known to grow by utilizing oligosaccharides such as fructooligosaccharides, and to produce butyric acid using acetic acid. The combination formulation of human milk oligosaccharides and fructooligosaccharides in this study is expected to show superior butyric acid production efficiency compared to each material alone.
[0188] <Test Example 2: Evaluation of the butyrate production-promoting effect of a composition combining 2'-FL and fructooligosaccharides under co-culture of Faecalibacterium prausnitzii and Bifidobacterium bifidum> The butyrate production-promoting effect of the above combination formulation on Faecalibacterium prausnitzii was evaluated by culturing Faecalibacterium prausnitzii and Bifidobacterium bifidum in a test medium containing both 2'-FL and fructooligosaccharides, according to the procedure shown below.
[0189] YCFAG medium or YCFA- medium was used as the culture medium. YCFAG medium was prepared in the same manner as in Test Example 1. The sugar sources used in the study were glucose, fructooligosaccharides (a mixture of 1-kestose, nystose, and 1-fructofuranosyl-D-nystose), 2'-FL, and a composition combining fructooligosaccharides (a mixture of 1-kestose, nystose, and 1-fructofuranosyl-D-nystose) and 2'-FL (Table 15). Glucose and fructooligosaccharides (catalog number 062-02381) were purchased from Fujifilm Wako Pure Chemical Industries, Ltd. 2'-FL was obtained from Kyowa Hakko Bio. Each sugar source was added to YCFA- medium to a final concentration of 5 g / L to prepare the test medium.
[0190]
[0191] We purchased Faecalibacterium prausnizzi (JCM31915) and Bifidobacterium bifidum (JCM1254) from the RIKEN BioResource Research Center. Single colonies of each strain were inoculated into YCFAG medium and incubated overnight at 37°C. The overnight culture solution was centrifuged at 6,000 x g for 5 minutes, and the supernatant was removed. 600 The suspensions were resuspended in YCFA medium to a ratio of 1.0. The suspensions of Faecalibacterium prausnizzi and Bifidobacterium bifidum were inoculated into each test medium at a 1 / 100 ratio and incubated at 37°C for 24 hours. All incubation was performed under anaerobic conditions. The culture solution was centrifuged at 15,000 rpm for 5 minutes at 4°C, and the culture supernatant was collected. The amount of short-chain fatty acids in the culture supernatant was measured using the YMC-Pack FA short-chain fatty acid analysis reagent (YMC Corporation).
[0192] Table 16 and Figure 4 show the butyrate concentration in the culture supernatant under each condition. In Table 16 and Figure 4, "*" and "**" indicate a significant difference compared to the group to which fructooligosaccharides were added alone (*: p < 0.05, **: p < 0.01, Tukey test). In addition, "#" and "##" in Table 16 and Figure 4 indicate a significant difference compared to the group to which 2'-FL was added alone (#: p < 0.05, ##: p < 0.01, Tukey test).
[0193]
[0194] Adding 2'-FL and fructooligosaccharides in predetermined ratios to Faecalibacterium prausnitzii and Bifidobacterium bifidum resulted in a significant increase in butyrate production (p < 0.01) compared to groups treated with each oligosaccharide alone. A synergistic increase in butyrate production was observed at mixing ratios of fructooligosaccharides and 2'-FL of 96:4, 94:6, 92:8, 90:10, 88:12, 86:14, 84:16, and 82:18.
[0195] <Test Example 3: Evaluation of the butyrate production-promoting effect of a composition combining 2'-FL and fructooligosaccharides in co-culture of Faecalibacterium prausnitzii and Bacteroides fragilis> The butyrate production-promoting effect of the above combination formulation on Faecalibacterium prausnitzii was evaluated by culturing Faecalibacterium prausnitzii and Bacteroides fragilis in a test medium containing both 2'-FL and fructooligosaccharides, following the procedure shown below.
[0196] The culture medium used was either YCFAG medium or YCFA- medium. YCFAG medium was prepared in the same manner as in Test Example 1. The sugar sources used in the study were glucose, fructooligosaccharides (a mixture of 1-kestose, nystose, and 1-fructofuranosyl-D-nystose), 2'-FL, and a composition combining fructooligosaccharides (a mixture of 1-kestose, nystose, and 1-fructofuranosyl-D-nystose) and 2'-FL (Table 17). Glucose and fructooligosaccharides (catalog number 062-02381) were purchased from Fujifilm Wako Pure Chemical Industries, Ltd. 2'-FL was obtained from Kyowa Hakko Bio. Each sugar source was added to YCFA- medium to a final concentration of 5 g / L to prepare the test medium.
[0197]
[0198] We purchased Faecalibacterium prausnizzi (JCM31915) and Bacteroides fragilis (JCM17586) from the RIKEN BioResource Research Center. Single colonies of each strain were inoculated into YCFAG medium and incubated overnight at 37°C. The overnight culture solution was centrifuged at 6,000 x g for 5 minutes, and the supernatant was removed. 600 The cultures were resuspended in YCFA medium to a ratio of 1.0. The suspensions of Faecalibacterium prausnizzi and Bacteroides fragilis were inoculated into each test medium at a 1 / 100 ratio and incubated at 37°C for 24 hours. All incubations were performed under anaerobic conditions. The culture solution was centrifuged at 15,000 rpm for 5 minutes at 4°C, and the culture supernatant was collected. The amount of short-chain fatty acids in the culture supernatant was measured using the YMC-Pack FA short-chain fatty acid analysis reagent (YMC Corporation).
[0199] Table 18 and Figure 5 show the butyrate concentration in the culture supernatant under each condition. In Table 18 and Figure 5, "*" and "**" indicate a significant difference compared to the group to which fructooligosaccharides were added alone (*: p < 0.05, **: p < 0.01, Tukey test). In addition, "#" and "##" in Table 18 and Figure 5 indicate a significant difference compared to the group to which 2'-FL was added alone (#: p < 0.05, ##: p < 0.01, Tukey test).
[0200]
[0201] Adding 2'-FL and fructooligosaccharides in predetermined ratios to Faecalibacterium prausnitzii and Bacteroides fragilis resulted in a significant increase in butyrate production (p < 0.05) compared to groups treated with each oligosaccharide alone. A synergistic increase in butyrate production was observed at mixing ratios of fructooligosaccharides and 2'-FL of 90:10, 80:20, 70:30, 60:40, 50:50, and 40:60.
[0202] <Test Example 4: Evaluation of the butyrate production-promoting effect of a composition combining 2'-FL and fructooligosaccharides in co-culture of Faecalibacterium prausnitzii and Akkermansia muciniphila> The butyrate production-promoting effect of the above combination formulation on Faecalibacterium prausnitzii was evaluated by culturing Faecalibacterium prausnitzii and Akkermansia muciniphila in a test medium containing both 2'-FL and fructooligosaccharides, according to the procedure shown below.
[0203] The culture medium used was either YCFAG medium or YCFA- medium. YCFAG medium was prepared in the same manner as in Test Example 1. The sugar sources used in the study were glucose, fructooligosaccharides (a mixture of 1-kestose, nystose, and 1-fructofuranosyl-D-nystose), 2'-FL, and a composition combining fructooligosaccharides (a mixture of 1-kestose, nystose, and 1-fructofuranosyl-D-nystose) and 2'-FL (Table 19). Glucose and fructooligosaccharides (catalog number 062-02381) were purchased from Fujifilm Wako Pure Chemical Industries, Ltd. 2'-FL was obtained from Kyowa Hakko Bio. Each sugar source was added to YCFA- medium to a final concentration of 5 g / L to prepare the test medium.
[0204]
[0205] We purchased Faecalibacterium prausnizzi (JCM31915) and Ackermansia muciniphila (JCM30893) from the RIKEN BioResource Research Center. Single colonies of each strain were inoculated into YCFAG medium and incubated overnight at 37°C. The overnight culture solution was centrifuged at 6,000 x g for 5 minutes, and the supernatant was removed. 600The cultures were resuspended in YCFA medium to a ratio of 1.0. The suspensions of Faecalibacterium prausnizzi and Akkermansia muciniphila were inoculated into each test medium at a 1 / 100 ratio and incubated at 37°C for 24 hours. All incubations were performed under anaerobic conditions. The culture solution was centrifuged at 15,000 rpm for 5 minutes at 4°C, and the culture supernatant was collected. The amount of short-chain fatty acids in the culture supernatant was measured using the YMC-Pack FA short-chain fatty acid analysis reagent (YMC Corporation).
[0206] The butyrate concentrations in the culture supernatant under each condition are shown in Table 20 and Figure 6.
[0207]
[0208] It was confirmed that adding 2'-FL and fructooligosaccharides in a predetermined ratio to Faecalibacterium prausnitzi and Ackermansia muciniphylla increased butyrate production compared to groups to which each oligosaccharide was added individually.
Claims
1. A composition containing at least one oligosaccharide A selected from the group consisting of fucosylated oligosaccharides and sialylated oligosaccharides, or a salt thereof, and a fructooligosaccharide or a salt thereof.
2. The composition according to claim 1, wherein the oligosaccharide A is fucosyl lactose and / or sialyl lactose.
3. The composition according to claim 1, wherein the oligosaccharide A is at least one oligosaccharide selected from the group consisting of 2'-fucosyl lactose, 3'-sialyl lactose, and 6'-sialyl lactose.
4. The composition according to claim 1, wherein the oligosaccharide A is 2'-fucosyl lactose and / or 3'-sialyl lactose.
5. The composition according to claim 1, wherein the oligosaccharide A is 2'-fucosyl lactose.
6. The composition according to claim 1, wherein the oligosaccharide A is 3'-sialyl lactose.
7. The composition according to claim 1, wherein the oligosaccharide A is 6'-sialyl lactose.
8. The composition according to claim 1, wherein the ratio of the content (mass%) of oligosaccharide A or its salt, based on the total amount of the composition, to the content (mass%) of fructooligosaccharide or its salt, based on the total amount of the composition, is 0.001 or more and 10 or less.
9. The composition according to claim 1, wherein, if it contains 2'-fucosyl lactose, the ratio of the content of 2'-fucosyl lactose (by mass%) relative to the total amount of the composition to the content of fructooligosaccharides (by mass%) relative to the total amount of the composition is 0.01 or more and 0.3 or less; if it contains 3'-sialyl lactose, the ratio of the content of 3'-sialyl lactose (by mass%) relative to the total amount of the composition to the content of fructooligosaccharides (by mass%) relative to the total amount of the composition is 0.01 or more and 0.3 or less; and if it contains 6'-sialyl lactose, the ratio of the content of 6'-sialyl lactose (by mass%) relative to the total amount of the composition to the content of fructooligosaccharides (by mass%) relative to the total amount of the composition is 0.1 or more and 9 or less.
10. The composition according to any one of claims 1 to 9, which is used in applications that utilize bacteria capable of decomposing and utilizing the oligosaccharide A and / or the fructooligosaccharide.
11. The composition according to claim 10, wherein the bacteria are capable of decomposing and utilizing the oligosaccharide A outside the cell.
12. The composition according to claim 10, wherein the bacterium is one or more selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, and Akkermansia muciniphila.
13. The composition according to claim 10, wherein the bacterium is Bifidobacterium bifidum.
14. The composition according to claim 10, wherein the bacterium is Bacteroides fragilis.
15. The composition according to claim 10, wherein the bacterium is Akkermansia muciniphila.
16. A composition for promoting butyrate production by butyrate-producing bacteria, as described in any one of claims 1 to 9.
17. The composition according to claim 16, wherein the butyrate-producing bacterium is a bacterium of the genus Faecalibacterium.
18. The composition according to claim 16, wherein the butyrate-producing bacterium is Faecalibacterium prausnitzii.
19. The composition according to claim 16, wherein the promotion of butyrate production is the promotion of butyrate production using bacteria capable of decomposing and assimilating the oligosaccharide A and / or the fructooligosaccharide.
20. The composition according to claim 19, wherein the bacteria are capable of decomposing and utilizing the oligosaccharide A outside the cell.
21. The composition according to claim 19, wherein the bacterium is one or more selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, and Akkermansia muciniphila.
22. The composition according to claim 19, wherein the bacterium is Bifidobacterium bifidum.
23. The composition according to claim 19, wherein the bacterium is Bacteroides fragilis.
24. The composition according to claim 19, wherein the bacterium is Akkermansia muciniphila.
